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1. Summary 
Leishmaniasis is a vector-borne parasitic disease of tropical and subtropical regions caused 
by the obligate intracellular protozoan parasite Leishmania and currently threatens over 350 million 
lives in 88 countries around the world with an estimated prevalence of 12 million and incidence of 
1.5-2 million. It also affects inhabitants of European subtropical regions, where a more fatal form of 
the disease occurs caused by co-infections of Leishmania/HTW. Since control strategies for the 
treatment and eradication of leishmaniasis improved little over the past decades, research driven 
advancements in diagnosis, treatment and prevention are prime necessities. 
The remarkable survival capabilities of Leishmania, the successful establishment of infection 
and multiplication in hostile environments of both the digestive tract of the sandfly vector and 
macrophages of mammalian host, are largely attributed to macromolecules that form a protective 
shield, the glycocalyx, around the parasite. This coat consists of surface-bound or optionally 
secreted mannose-rich glycoconjugates that are thought to be key determinants of Leishmania 
viability and virulence. 
The building blocks for the assembly of different glycoconjugates are the activated 
nucleotide sugar donors, such as GDP-mannose and Dol-P-mannose. The activation of mannose 
from Man-6-PC>4 to GDP-mannose or Dol-P-mannose donors requires the sequential enzymatic 
action of phosphomannomutase (PMM), GDP-mannose pyrophosphorylase (GDPMP), and Dol-P-
mannose synthase (DPMS). Optionally the hexose-monophosphate pool derived Frc-6-P04 can also 
be converted to Man-6-P04 in a reaction catalyzed by phosphomannose isomerase (PMI), to feed the 
mannose activation pathway. 
Given the high rate of glycoconjugate synthesis in Leishmania, the proper mannose supply is 
predicted to be of prime importance for these parasites. Therefore, in our studies we tried to 
elucidate the importance of the mannose activation pathway by a reverse genetics approach, and to 
estimate its specific impact on Leishmania viability, growth, glycoconjugate synthesis, and 
virulence that eventually may lead to identification of new drug targets and novel treatments for 
leishmaniasis. 
The genes of Leishmania mexicana mannose activation pathway were homology cloned and 
sequenced to generate Leishmania mutants lacking function of the enzyme cascade at different 
levels. Remarkably, in contrast to different pathogenic fungi, yeast species or humans - wherein 
functional lack of mannose activation pathway, leading to complete lack of glycoconjugates, is 
incompatible with life - in Leishmania, targeted gene deletion still led to viable mutants. These 
results doubtlessly showed that mannose-containing glycoconjugates, in contrast to a former report 
(Ilgoutz, 1999, EMBO J) also in L. mexicana, are not essential for Leishmania viability and 
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therefore may provide a unique model system for studies on eukaryotic glycoconjugate assembly. 
As it was anticipated, the mannose activation pathway mutants showed a complex phenotype with 
the lack of different mannose-containing glycoconjugates, which affected Leishmania virulence to 
various extents. The mutants lacking PMI or DPMS enzymes remained infectious, although were 
attenuated, while PMM or GDPMP lacking mutants were found to be avirulent. 
Our results identify the mannose activation pathway as a virulence pathway in Leishmania 
that consequently may serve as an appealing potential drug target for combating leishmaniasis. In 
contrast to earlier unsuccessful attempts to unfold the mystery of Leishmania virulence by targeting 
single mannose-containing glycoconjugates, a new view is arising based on our novel approach, 
where the pathway of glycoconjugate biosynthesis was targeted. This novel view strongly suggests 
that instead of a single mannose-containing glycoconjugate, the various redundant glycan motifs, 
which are shared between different classes of glycoconjugates may be responsible for the 
evolutionarily successful virulence of Leishmania. 
The avirulent Leishmania strains described in this study may also be potentially further 
developed to efficient vaccines for the prevention of leishmaniasis. 
2. Összefoglalás 
Leishmaniasis a trópusi és szubtrópusi területek endémiás, vektor teij eszetette parazitás 
betegsége, amelyet az obligát intracelluláris protozoon parazita Leishmania okoz és amely jelenleg 
többmint 350 millió ember életét veszélyezteti a világ mintegy 88 országában, körülbelül 12 milliós 
becsült prevalenciával és 1,5-2 milliós incidenciával. A betegség szintén megtalálható Európa 
szubtrópusi területein, ahol egy sokkal végzetesebb kimenetelű formája fordul eló, amelyet 
Leishmania/HYV együttes fertőzése okoz. Mivel az elmúlt évtizedek alatt a leishmaniasis 
kezelésének és eradikációjának a kontrol stratégiái kevéssé fejlődek, a kutatás ösztönözte 
előrehaladás a diagnózis és prevenció területén elsődleges fontosságú. 
A Leishmania hihetetlen túlélőképessége, sikeres fertőző képessége és szaporodása, mind a 
lepkeszúnyog vektor emésztőrendszerének és az emlős gazda makrofágjainak kedvezőtlen 
körülményei között, nagyrészt a parazita felszínén található makromolekulák által formált 
védőpajzsnak, a glikokálixnak, tulajdonítható. Ez a réteg, felszínhez kötött vagy esetlegesen 
szekretált mannózban gazdag glikokonjugátokból áll, amely molekulákat a Leishmania 
életképességének és virulenciájának kulcsfontosságú meghatározójaként tartanak számon. 
A különféle glikokonjugátok összeszereléséhez az építőkövek az aktivált nukleotidcukor 
donorok, mint a GDP-mannóz és dolikol-P-mannóz. A mannóz mannóz-6-P04-ból GDP-mannózzá 
vagy dolikol-P-mannózzá való aktiváláshoz enzimek sorának - foszfomannomutáz, GDP-mannóz-
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pirofoszforiláz és dolichol-foszfomannóz mutáz - összehangolt működésére van szükség. 
Esetlegesen a hexóz-monofoszfát raktárból származó Frc-6-P04 is táplálhatja a mannóz aktiválás 
biokémiai útját, amely szintén átalakulhat Man-ő-PCVtá egy a foszfomannóz-izomeráz katalizálta 
reakció révén. 
A Leishmania glikokonjugátok nagysebességű szintézise miatt a megfelelő mannóz ellátás 
valószínűleg elsődleges fontosságú a paraziták számára. Ezért kísérleteinkben próbáltuk tisztázni a 
mannóz aktiválás biokémiai útjának jelentőségét reverz genetikai megközelítés segítségével, és így 
felbecsülni annak jelentőségét a Leishmania életképessége, növekedése, glikokonjugát szintézise és 
virulenciája szempontjából. - ami végül új gyógyszercélpontok azonosításához és a leishmaniasis 
újszerű kezeléséhez is vezethet. 
Leishmania mexicana mannóz aktiválás biokémiai útjának génjeit homológiájuk alapján 
kiónoztuk, majd szekvenáltuk, azért hogy lépésenként ennek az enzimláncolatnak a különböző 
szintjein levő hiánnyal rendelkező mutánsokat tudjunk előállítani. Rendkívüli módon, ellenben 
különféle kórokozó gomba és élesztőgomba fajokkal valamint emberrel - amelyekben a mannóz 
aktiválás biokémiai útjának hiánya, amely a glikokonjugátok teljes hiányához vezet, az élettel 
összeegyeztethetetlen - Leishmania ban génjeinek specifikus hiánya mégis életképes mutánsokat 
eredményez. Ezek az eredmények kétségtelenül bizonyítják, hogy a mannóz-tartalmú 
glikokonjugátok, ellenben egy korábbi beszámolóval (Ilgoutz, 1999, EMBO J) szintén L. 
mexicanában, nem alapvetően fontosak a Leishmania életképességéhez, ezért azok kitűnő 
modellrendszerként szolgálhatnak az eukarióta glikokonjugát szintézis tanulmányozására. Amint 
reméltük, a mannóz aktiválás biokémiai útjának mutánsai egy összetett fenotípust mutattak, a 
különféle mannóz-tartalmú glikokonjugátok hiányával, amely különböző mértékben befolyásolta a 
Leishmania virulenciáját. Mutánsok amelyekből a foszfomannóz-izomeráz vagy a dolichol-
foszfomannóz-mutáz hiányzott fertőzőképesek maradtak, bár legyöngítettek, míg a 
foszfomannomutáz vagy a GDP-mannóz-pirofoszforiláz hiányos mutánsok fertőzésképtelennek 
bizonyultak. 
Eredményeink a mannóz aktiválás biokémiai útját, mint virulencia biokémiai útat 
azonosítják Leishmaniában, ami következésképpen potenciálisan vonzó gyógyszer-célpontként 
szolgálhat a leishmaniasis elleni küzdelemben. Ellenben a korábbi sikertelen próbálkozásokkal a 
Leishmania virulanciája titkának feltárására - amikoris egyes mannóz-tartalmú glikokonjugátokat 
céloztak - egy új nézet körvonalazódik újszerű megközelítésünk alapján, amely a glikokonjugátok 
bioszintézisének útját célozta. Ez az új nézet erősen sugallja, hogy az egyes mannóz-tartalmú 
glikokonjugátok helyett, azok különböző nagyszámban jelenlévő glikán motívumai - amelyek 
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részben közösek a glikokonjugátok különféle osztályaiban - lehetnek felelősek a Leishmania 
evolúciósan sikeres virulenciájáért. 
Az avirulens Leishmania mutáns törzsek, amelyek ebben a tanulmányban leírásra kerültek, 
potenciálisan továbbfejleszthetőek lehetnek hatékony oltóanyaggá a leishmaniasis megelőzésére. 
3. Introduction 
3.1 A broader context of tropical diseases 
Since 'The Great White of Lambaréné' established his hospital in a province of French 
Equatorial Africa, nowadays Gabon, the global awareness for public health problems of the Third 
World still has not been sufficiently improved. Via his testimony, Albert Schweitzer called the 
attention of Nations on the must of easing the Third World people's misery. Ultimately, his devoted 
life was recognized by Nobel Peace Prize in 1952 for all the efforts on behalf of the 'Brotherhood of 
Nations'. 
Over decades, hundreds and thousandsl^Sdjjeeq^evoted their lives to relieve the pain of the 
poorest; despite of these efforts the public health situation of the Third World is still unresolved. In 
fact, recently WHO has reported a further increase in the burden of tropical diseases. These facts 
define tropical research and innovative translation of its breakthrough achievements as essential 
activities in combating diseases of the Third World. Unfortunately, prioritization of research funding 
is still more than unsatisfactory, since only about 10% of global research funds are allocated to 
neglected tropical diseases that make up approximately 90% of the disease burden in our planet 
(Global Forum for Health Research, 2002). 
Besides the dedicated efforts of WHO, the pharmaceutical industry still seems to be divided 
in giving support for easing suchVburning health issues of the poorest. However, a positive trend is 
being outlined recently, showing that some pharmaceutical key players are becoming committed to 
support the Third World's health. While sacrificing bits of their profit, they can decently ease the 
burden of tropical diseases via supplying medicines at production cost or funding non-profit 
research institutes for combating tropical diseases. At the same time, WHO needs to convince others 
via long-lasting lobbying about just simply further producing some of the first line drugs of the 
medical arsenal against tropical diseases. 
If there are still some doubts about the necessity of dealing with these emerging diseases, it 
should not be forgotten, that just a century ago Europe also knew these diseases very well. 
Moreover, according to recent scenarios of global climate change, we may easily face them again in 
the near future, since increasing temperature and rainfall is shown to be associated with increased 
9 
number of epidemics for several tropical diseases (Global environmental change, WHO website). 
Additionally, from an epidemiological aspect, the high risk of rapid diseases spread in our "global 
village" spiced with decent worldwide migration trends, also needs the attention of professionals. 
Some serious problems are already at the doorstep, such as the world widely increasing 
incidence of drug resistant bugs, the frequency of opportunistic HIV co-infections and the lack of 
preventive vaccination. These global challenges certainly call for global solutions. 
Taken together, tropical research that elucidates new cellular processes and identifies novel 
drug targets that can lead to more efficient treatment strategies and better diagnostics is of prime 
importance for the control of tropical diseases, especially for the citizens of the Third World. Of 
course, the ultimate global answer for the tropical disease burden, in alignment with WHO efforts, is 
the development of efficient vaccines for the prevention of these maladies. 
3.2 Leishmaniasis a parasitic protozoan disease of tropics and subtropics 
Three tropical diseases - African trypanosomiasis, Dengue fever and Leishmaniasis -belong 
to the highest priority category according to the disease burden, epidemiology trend and health 
economy based prioritization list of WHO (Remme JH, 2002). 
Leishmaniasis is a vector-borne parasitic disease of tropical and subtropical regions of both 
the Old and New World. The causative agents of leishmaniasis are obligate intracellular protozoan 
species belonging to the Leishmania genus that are transmitted by the bite of a 2-3 millimeter-long 
insect vector, the sandfly (Phlebotomus or Lutzomyia, in the Old World or New World respectively) 
during blood feeding. Leishmania currently threaten over 350 million lives in 88 countries around 
the world with an estimated prevalence of 12 million, incidence of 1.5-2 million and disability 
adjusted life years (DALY) lost of 2.4 million (Fig.l). Leishmaniasis also affects citizens from 
subtropical regions of European countries such as France, Italy, Greece, Malta, Spain and Portugal. 
Indeed the incidence of leishmaniasis is sharply increasing in these regions that mainly consist of a 
more fatal form of the disease caused by co-infections of Leishmania/HLV (Fig.l). Leishmania 
infection can lead to diverse animal and human diseases, which clinically exhibit a rather wide 
spectrum from cutaneous, the mostly skin localized to visceral the generalized forms. The clinical 
pathology of Leishmania infection is determined by several factors of the "infectious triangle", 
namely by the host immune system and nutritional status, the given Leishmania species involved 
and the characteristics of the sandfly vector. 
The most common form of the disease is cutaneous leishmaniasis, also known as espundia, 
which develops single skin ulcers on the most exposed, easily sandfly-bitten parts of the body, such 
as the ears, face, neck and extremities. This lesion usually remains localized and typically heals 
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spontaneously within 6 months to 2 years, but can also be accompanied by enormous tissue 
destruction and scarring eventually leading to stigmatization and social prejudice of the patient. 
Fig.l. Global distribution of reported cases of leishmaniasis and LeishmanialWW co-
infection (source: Leishmaniasis and HIV co-infection, WHO Homepage) 
Cutaneous leishmaniasis sometime is not limited to a single location, but develops numerous 
small, disseminated nodular skin lesions without self-healing potential. Developing this form of 
leishmaniasis, the diffuse cutaneous Leishmaniasis (DCL), is highly dependent on host factors such 
as the immune status or inherited genetic susceptibility loci, but to a limited extent, it is also 
influenced by the Leishmania species involved in the infection. Cutaneous leishmaniasis is 
predominantly caused by L. major/L. tropica and L. mexicana/L. amazonensis species in the Old and 
New Worlds respectively. 
The mucocutaneous form of Leishmaniasis is caused by several South-American Leishmania 
species, most frequently by L. brasiliensis. Lesions predominantly occur on mucous membranes of 
the nose, mouth, throat cavities and the surrounding tissues. These lesions often lead to partial or 
total destruction of soft tissues that resembles those of lepromatous leprosy and result in severe 
scarring, disfiguring and frequently consequent humiliation and casting out from the society. 
The visceral form of leishmaniasis, also known as kala azar, is the most devastating, which 
unless treated, leads to lethality approaching 100% (Molyneux DH, 1983; Leishmaniasis, WHO 
website). In this form, the primary sites of active infection are the spleen, liver and bone marrow, 
but parasites widely spread in the whole body via the infected immune cells and body fluids. 
Visceral leishmaniasis is clinically characterized by high fever, severe weight loss, hepato-, 
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splenomegaly, and occasionally severe anemia that non-specific symptoms make diagnosis rather 
difficult. Nowadays, the most emerging type of visceral leishmaniasis occurs in HIV-infected 
individuals as severe opportunistic infection (Wolday D, 1999). Most of these LeishmanialHIV co-
infected patients develop a considerably serious, fulminant and rapidly progressing form of visceral 
leishmaniasis, caused by a synergistic attack against the immune system. The causative agents of 
visceral form are predominantly two species, the L. donovani and L. infantum/L. chagasi. 
Human cases of leishmaniasis are usually zoonoses, when the parasite is transmitted from 
reservoir species such as dogs, rodents, foxes, jackals and wild rodents (gerbils, sloths and 
opossums) to humans via the bite of the sandfly vector when feeding a blood meal. However, 
anthroponotic, from human to human, transmission of infection also occurs which is mediated by 
sandfly vectors. Examples for such an anthroponotic transmission are the urban cutaneous 
leishmaniasis caused by L. tropica and the visceral leishmaniasis in India caused by L. donovani, 
where sandfly mediated human-to-human transmission is indeed the major source of disease spread. 
3.3 Leishmaniasis control strategies 
Control strategies for the treatment and eradication of leishmaniasis has improved little over 
the past decades. Although some recently launched WHO programs facilitated advancements in 
diagnosis, treatment and prevention of leishmaniasis, proper disease control is still far from being 
satisfactory. Furthermore, no defined, safe vaccines yet exist for the prevention of leishmaniasis and 
only few drugs are available for treatment (Croft SL, 1997; Davies CR, 2003). For about half a 
century, pentavalent antimonials have been used as first line drugs for the treatment of all forms of 
leishmaniasis. Parasite resistance to these drugs has increased over decades and reached a significant 
level by now. Therefore, treatment with second line drugs, such as amphotericin B and pentamidine 
is more frequent, but unfortunately, they carry notable risk of serious toxic side effects. Remarkably, 
a "reinvented" application of an originally used anticancer drug, miltefosine, is in the late phase of 
clinical development or registered already in some countries (e.g. India) and shows high success 
rates of healing in both, visceral and cutaneous leishmaniasis. However, care should be taken since 
miltefosine is teratogenic in animal models, therefore it should not be prescribed to pregnant woman 
or to those of childbearing age without effective birth control. An additional shadow that falls on 
this success story is the appearance of miltefosine resistant Leishmania strains, which indeed 
underlines the need of testing multiple drug combination regiments to prevent emergence of parasite 
resistance to novel medicines. 
3.4 Biology of Leishmania 
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Leishmania species evolutionarily represent one of the earliest eukaryotic organisms that 
possess mitochondria (Leipe DD, 1993) and form the genus Leishmania that taxonomically belongs 
to Trypanosomatidae family, Trypanosomatina suborder, and Kinetoplastida order (Fig.2). These 
ancient unicellular eukaryotic organisms have several peculiar cellular organelles (e.g. kinetoplast -
that also refers to the order, and glycosomes) with unique cellular functions. Numerous 
morphologically distinct developmental forms of a given Leishmania species exist, which reflects 
adaptation to diverse environments of their digenetic life cycle. Principally, Leishmania alternate 
between the colonization of an insect vector by the extracellular, slender shape, flagellated and 
motile promastigotes, and that of a mammalian host by the obligatory intracellular, non-flagellated, 
round shape amastigotes (Fig.3). 
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Fig.2. Phylogenetic tree based on the analysis of 16S rRNA sequences showing the 
evolutionary distance between organisms (Sogin ML, 1989). 
Female sandflies acquire the parasites during blood feeding when they bite a Leishmania 
infected host. Ingested Leishmania reside within a peritrophic membrane that covers the blood meal 
in the sandfly intestine, here they transform to procyclic promastigotes, the short, motile flagellated 
form. Shortly after the peritrophic membrane is disrupted, the parasites acquire a slightly longer, 
slender shape and transform to the nectomonad promastigote form. The nectomonads are released to 
the lumen of the midgut, where with their flagella they intercalate between the microvilli of the 
epithelial cells and start to replicate in the mid-gut lumen against the harsh environment surrounding 
them. From this stage, via the free-swimming or cuticule attached haptomonad promastigote form 
they transform to highly motile, free-swimming, non-dividing metacyclic promastigotes that are 
highly infective and migrate to the sandfly foregut, where they get prepared for transmission. Near 
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the mouthpart, they start to secrete highly glycosylated macromolecules that form a "plug", which 
causes regurgitation, a functional disturbance of the sandfly digestive tract (Rogers ME, 2004). This 
strategy of the highly infective metacyclic promastigotes significantly increases the success of 
transmission to a new host. 
transformation of 
amastigotes to 
promastigotes in 
the sandfly midgut 
transmission by the bites of 
infected female sandflies 
opsonization by 
serum components 
and efficient uptake 
by macrophages 
infected macrophages or 
amastigotes are taken up 
by sandflies during blood 
feeding 
transformation of 
promastigotes to 
amastigotes 
Nature Reviews | Immunology 
Fig.3. Leishmania life cycle (adapted from Sacks D, 2002). 
In the skin of the vertebrate host, the freshly inoculated Leishmania get rapidly 
phagocytozed by macrophages or dendritic cells. These infected cells, when they migrate, carry 
Leishmania around the body and so facilitate the further spread of parasites via a 'by-stander' effect. 
Inside the host cell, triggered by the harshly changing environment, promastigotes rapidly (within 
12-24 hours) transform to amastigotes. This short, non-motile, intracellular form of Leishmania is 
able to block the normal maturation of phagolysosomes and rapidly multiply under the surrounding 
hostile conditions that progressively result in the formation of parasitophorous vacuoles. This 
process leads to the gradual expansion of parasitophorous vacuoles that eventually rupture and the 
highly infective amastigotes are released to the body fluids and can colonize new host cells. 
The remarkable survival capabilities of Leishmania throughout its life cycle, such as 
successful establishment of infection via subverting the innate and adaptive immune system and 
multiplication in hostile environments of both the sandfly digestive tract and host macrophages, are 
largely attributed to molecules that predominantly form a developmentally distinct surface coat, the 
glycocalyx, as a protective shield around the parasite. These primarily surface-bound or optionally 
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secreted sugar-rich glycoconjugate molecules are thought to be key determinants of Leishmania 
virulence via multiple functions attributed to them. 
3.5 Immunology of Leishmania infection 
To ensure its survival and reproduction in the host organism, Leishmania must compromise 
the defense mechanisms of the host immune system. This includes some rather unspecific ways for 
targeting the innate immune system and more sophisticated and less understood approaches for the 
derangement of the delicate balance of cellular Thl and Th2 responses of the adaptive immune 
system (Reiner SL, 1995). In all these processes, surface or secreted glycoconjugate molecules are 
assumed to be involved, as key players. 
3.5.1 Subversion of innate immune system by Leishmania 
On each bite, during blood feeding of Leishmania-'mfected sandflies, approximately 10-100 
metacyclic, highly infective promastigotes are inoculated into the skin of the mammalian host, 
where the parasites immediately encounter the humoral defense mechanisms of the innate immune 
system, specifically the alternative and lectin pathways of the complement system. Both metacyclic 
promastigotes and amastigotes are resistant to complement lysis that is believed to be conferred by 
different surface glycoconjugates (Mosser DM, 1985; Sacks DL, 1989). 
In the host, metacyclic promastigotes immediately activate the alternative complement 
pathway, which leads to binding of C3 convertase activated C3 (C3b) to an abundant glycoconjugate 
component of the Leishmania glycocalyx coat, the lipophosphoglycan (LPG). Although this leads to 
the subsequent recruitment of the membrane attack complex (MAC), the lethal process of MAC 
insertion to the plasma membrane appears to be hampered by the specifically thick layer of LPG that 
can physically inhibit the direct access of MAC to the parasite surface (Hall BF, 1991). Shielding of 
promastigotes from the humoral defense is further supported by a surface metalloproteinase, the 
leishmanolysin (gp63) an enzyme that can rapidly convert the active LPG-bound C3b into an 
inactive form, iC3b (Brittingham A, 1996; Joshi PB, 1998), thus undermining the further activation 
of the complement cascade. On the other hand, C3b and iC3b also facilitate the attachment of 
opsonised parasites to macrophages and skin dendritic cell complement receptors CR1 and CR3 
respectively (reviewed in Hall BF, 1991; Brittingham A, 1996) thus assisting the internalization of 
promastigotes and ultimately the host cell invasion. Although Leishmania are internalized, they can 
act as a 'Trojan horse' for impeding macrophage activation. Several strategies are utilized by 
promastigotes to exploit macrophages, such as interfering with intracellular signal transduction 
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pathways or delaying the phagosome-lysosome fusion as examples, via secreted molecules, incuding 
LPG (+PPGs). These mechanisms allow the promastigotes to be protected from lysosomal 
hydrolases until the environmental stimuli signaled transformation to highly resistant, obligatory 
intracellular amastigotes is undertaken (Desjardins M, 1997). 
Astonishingly amastigotes, while residing in the newly formed, strongly acidified (pH 4.7-
5.2), endosomal/lysosomal hydrolase-rich parasitophorous vacuoles, in contrast to most bacterial, 
fungal or protozoan pathogens, do not only survive, but indeed able to multiply (Alexander J, 1975; 
Antoine JC, 1990; Prina E, 1990; Lang T, 1994; Russell DG, 1995a,b), even if they do not express 
the protective macromolecule, LPG (Pimenta F, 1991). Host cells, besides serving as Trojan horse 
of parasites at hiding from the immune system, they also assist the spread of parasites when they 
migrate throughout the body. For successful parasitization, Leishmania need to intervene 
macrophage activation, a process that normally via production of high levels of nitric oxide and 
reactive oxygen intermediates leads to intracellular killing of invaders (Liew FY, 1990; Stenger S, 
1994, 1996; Murray HW, 1999). Leishmania seem to interfere with macrophages on various ways 
such as inhibition of the iNOS induction and consequent NO production (Proudfoot L, 1995, 1996; 
Piedrafita D, 1999; Liew FY, 1990), inhibition of NADPH oxidase activation and consequent 
reactive oxygen production (reviewed in Descoteaux A, 1993) or scavenging free radicals (Chan J, 
1989) that are assumed to be mediated by parasite glycoconjugates like the 
glycoinositolphospholipids (GIPLs) or LPG. 
3.5.2 Hijacking the adaptive cellular defense mechanisms of the immune system 
by Leishmania 
The mechanism how Leishmania can derail normal host adaptive immune responses has 
been investigated for decades. According to our current understanding, mostly based on infection 
models of inbred mice strains with L. major, the resistance or susceptibility to Leishmania infection, 
likewise to many intracellular pathogens, also largely depends on the type of CD4+ T-helper (TH) 
cell response, while CD8+ cytotoxic T cell and B cell responses play somewhat limited role. Indeed 
these experiments, as model system, were the first in vivo demonstration of the relevance of T-
helper 1/ T-helper 2 (TH1/TH2) balance in disease outcome (Sacks D, 2002 and references therein). 
As it was shown, if during the course of infection the differentiation of CD4+ TH cells is polarized 
toward a dominating THI cell response, then the lesion usually heals rapidly via induction of 
macrophage activation and consequent intracellular killing of Leishmania. On the other hand, if TH2 
response predominates, which favors a largely humoral immune response, the infection intends to 
persist, spread and lesions become chronic in the lack of macrophage activation (Fig.4). 
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Fig.4. TH1/TH2 balance and the outcome of leishmaniasis (adapted from Sacks D, 2002). 
The early events of infection in susceptible (e.g. Balb/c, a model of non-healing lesions of 
human leishmaniasis) or resistant (e.g. C57B1/6, a model of healing human lesions) mice are rather 
similar and includes early production of interleukin-4 (IL-4) and other type-2 cytokines by CD4+ T 
cells (Stetson DB, 2002). However, later response becomes polarized towards THI or TH2 
dominance that is highly dependent on the presence or lack of IL-12 produced by the infected 
macrophages (Heinzel FP, 1993; Sypek JP, 1993). Late events in susceptible mice include 
maintenance of TH2 response in the lack of proper IL-12 stimulation that parallels with production 
of IL-4, IL-13, IL-10 and TGF-[3, which prevents eventually the macrophage activation and parasite 
killing (Bogdan C, 2000). When a proper IL-12 stimulation is present, likewise observed in resistant 
mice, high levels of IFN-y and TNFa are produced that upregulates iNOS expression and activates 
intracellular killing in the infected macrophages, that eventually leads to eradication of parasites and 
healing of the lesion (Bogdan C, 1996). 
The role of Leishmania surface or secreted glycoconjugate molecules in shifting the immune 
response toward Th2 dominance at non-healing lesions is being heavily investigated and likely stays 
in focus of interest for a while, since better understanding of these mechanisms can facilitate the 
development of preventive vaccines. 
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3.6 Leishmania genetics 
Leishmania are unicellular diploid eukaryotes that reproduce asexually by division, therefore 
exhibit a rather clonal population structure (Tibayrenc M, 1991). However, the plasticity of their 
genome, including chromosomal rearrangements and DNA amplification is a well-known 
phenomenon (reviewed by Segovia M, 1997). This can ensure the essential heterogeneity for 
Leishmania population, which besides allowing flexible adaptation to changing natural 
environments also advantageous for coping with artificial evolutionary selection pressure, such as 
the drugs when via for example gene amplification Leishmania can develop drug resistance. 
Besides the nuclear DNA, approximately 15% of the Leishmania genome is packed in a 
single mitochondrion, the kinetoplast. The kinetoplast DNA, which corresponds to the mammalian 
mitochondrial DNA, is replicated not separately, but together with the nuclear DNA in a coordinated 
manner. 
Among other peculiar features of the Leishmania genome, some notably characteristic ones 
are the complete lack of introns and extensive sets of collinearly arranged genes, which result in 
gigantic polycistronic primary transcripts that are further trans-spliced and polyadenylated to 
monocistronic mRNAs whose steady state levels are individually regulated by post-transcriptional 
mechanisms (Myler PJ, 1999). 
During the last decade, the molecular geneticist's arsenal for dissecting genetically 
Leishmania, increased reasonably with respect to a variety of positive and negative selectable 
markers, reporter genes, episomal and integrating expression vectors, highly efficient gene 
replacement by homologous recombination and transposable elements that have been developed and 
used extensively for reverse genetic approaches (summarized in Beverley SM, 1998; Clayton CE, 
1999). Moreover, the Leishmania Genome Network initiative, that was established about a decade 
ago with the aim to sequence the genome of L. major (Friedlin strain), as model organism, for 
facilitating Leishmnaia research and consequently disease control strategies, has been accomplished 
in 2005 (Ivens AC, 2005). 
4. Surface glycocalyx components and glycoconjugate virulence factors of 
Leishmania 
Leishmania species synthesize vast amounts of glycosylated cell surface or secreted 
molecules, which form a highly resistant glycocalyx shield that serves as a multifunctional 
protective barrier during their life cycle. The molecular composition of the glycocalyx is highly 
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dependent on the stage of their life cycle. Promastigotes are shielded with a 20-40 nm thick layer of 
highly glycosylated molecules that predominantly consist of unusual glycoinositolphospholipids 
(GIPLs), a unique family of phosphoglycan-modified macromolecules that encompasses lipid-linked 
(lipophosphoglycan or LPG), protein-linked (proteophosphoglycans or PPGs) and unlinked forms 
(phosphoglycans or PGs), additionally highly conserved protein-linked glycosylphosphatidylinositol 
(GPI) membrane-anchors, and glycoproteins with uncommon N-linked glycans. The intracellular 
amastigotes, in contrast to promastigotes, lack such a thick glycocalyx layer and are abundantly 
coated with a layer of GIPLs and different lipid containing molecules acquired from the host cell. 
Investigating the role of these abundant mannose- and galactose-rich glycoconjugates in parasite 
survival and successful invasion of host and vector organisms has been in the focus of Leishmania 
research for the past decade. 
4.1 Lipophosphoglycan (LPG) 
In particular, the major cell surface glycoconjugate of Leishmania, LPG has been the most 
thoroughly studied molecule to date. Promastigotes express about 1-5 x 106 copies of LPG per cell, 
while amastigotes do only about 100 or 1000 copies that is moreover structurally distinct from the 
promastigote one (Glaser TA, 1991; Moody SF, 1993). This glycolipid macromolecule generally 
consist of four domains: a conserved membrane anchor of l-O-alkyl-2-lyso-
phosphatidyl(myo)inositol, followed by a conserved core structure of diphosphoheptasaccharide, 
and variable number (20-40) of phosphodisaccharide repeats with species- and stage-specific side 
chain modifications, and capped with a variable, dominantly mannose-rich structure (Fig. 5; 
McConville MJ, 1993a). The membrane anchor domain of LPG predisposes the molecule to be 
membrane bound; however, LPG can be shed from the parasite surface and released to the 
extracellular space (Handman E, 1984; King DL, 1987), a mechanism that may allow Leishmania to 
get rid of glycocalyx bound host-derived defensive factors. LPG is believed to be a key molecule of 
Leishmania virulence in the mammalian host, with numerous functions attributed to it, such as 
conferring promastigote complement resistance in the mammalian host (Sacks DL, 1989), mediating 
attachment and uptake of promastigotes by macrophages (Handman E, 1985; Da Silva RP, 1989; 
Talamas-Rohana P, 1990), shielding against macrophage phagolysosomal hydrolases (Turco SJ, 
1992) and inhibiting respiratory burst (Chan J, 1989) most likely via inhibition of host cell signal 
transduction pathways of protein kinase C (reviewed in Descoteaux A, 1993; Giorgione JR, 1996) 
and intracellular calcium (Eilam Y, 1985). Furthermore, the inhibition of phagolysosome maturation 
in macrophages (Desjardins M, 1997) and the transendothelial migration of monocytes (Ho JL, 
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Fig.5. Mannose-containing glycoconjugates of Leishmania with epitops for monoclonal antibodies 
and concanavalin A binding sites applied in our studies, as well as the source of mannose residues 
(GDP-Man or Dol-P-Man activated mannose donor) indicated. 
1996; Lo SK, 1998), suppression of interleukin (IL)-ip and tumour necrosis factor-a, likewise 
downregulation of inducible NO synthase (iNOS) and inhibition of macrophage IL-12 (Proudfoot L, 
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1996; Piedrafita D, 1999) considered to be key events of Leishmania infection mediated by LPG. 
The parallels drawn between these functional studies and data showing the loss of infectivity 
observed for LPG-deficient spontaneous mutant of L. major (Handman E, 1986) or chemical 
mutagenesis generated L. donovani or L. major (King DL, 1988; Elhay M, 1990; McNeely TB, 
1990) reinforced the role of LPG as multifunctional virulence factor in Leishmania, although these 
strains may indeed carry rather uncharacterized mutations because of the nature of mutagenesis. 
Moreover, the final prove for such an overall role of LPG in Leishmania infectivity, via generating 
revertants that would reexpress LPG and consequently may have restored infectivity, was never 
shown (Beverley SM, 1998). Furthermore, some described 'LPG-deficient' L. donovani mutants 
(Descoteaux A, 1995, 1998) have defects more than LPG biosynthesis, since their 
proteophosphoglycan (Ilg T, 2000a; PPG reviewed in Ilg T, 2000b; see also in next section) 
synthesis is also affected. 
Above observations, underline the necessity of applying state-of-art technologies of targeted 
gene replacement, instead of mutagenesis, for specifically generating and reverting Leishmania 
mutants in studies that aim to clarify the role of Leishmania glycoconjugate virulence factors. 
Such a targeted gene replacement approach was utilized recently in Leishmania for the 
elucidation of the role of the glycoconjugate virulence factor LPG, when lpgl and lpg2 genes that 
are involved in LPG synthesis were targeted. Lpgl gene encodes a putative P-galactofuranosyl [P-
Galf] transferase localized in the Golgi apparatus and known to be crucial for the addition of an 
unusual internal P-Galf residue to the LPG diphosphoheptasaccharide core (Huang C, 1993; de 
Lederkremer RM, 1995). Lpg2 gene encodes a Golgi GDP-mannose transporter (Ma D, 1997) 
involved in both, LPG and PPG biosynthesis. 
Targeted gene replacement of L. major lpgl resulted attenuated parasites in line with the 
described role of LPG (Spath GF, 2000). However, in contrast to the former report, targeted deletion 
of lpgl gene in L. mexicana did not affect the virulence of parasites to macrophages or mice (Ilg T, 
2000a). Several explanations may exist for this inconsistent finding: (i) for L. major P-Galf may be 
important for the biosynthesis of macromolecules other than LPG, which is indeed suggested 
(McConville MJ, 1993b), and therefore the lpgl mutant phenotype would not correspond to an 
exclusive lack of LPG, but also other glycoconjugates. (ii) LPG may have slightly different 
importance at the phase of transmission and/or establishment of Leishmania infection, which is 
suggested by the delayed onset of mouse pathology with L. major lpgl mutants versus L. mexicana 
ones that are fully virulent. 
Observations with different Leishmania species, when lpg2gene was targeted are similar. L. 
mexicana knockouts lacking lpg2 exhibited a 'glycotype' of deficient phosphoglycan repeat motifs, 
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which affects not only LPG, but also PPGs and free phosphoglycans. Although lacking 'major 
virulence factors', these L. mexicana mutants remained fully infectious to macrophages or mice (Ilg 
T, 2001). In L. major, the lack of lpg2 gene led to strong attenuation of the parasites, although, in 
contrast to a former report of the same group which stated lpg2 deficient L. major parasites being 
avirulent (Descoteaux A, 1995) these mutants were able to persist in the host (Spath, 2003), 
therefore potentially may develop pathology (especially in the case of HIV coinfection). This later 
risk was indeed shown recently by the reisolation of emerging, still lpg2 negative, but highly 
infectious parasites from mice (Spath, 2004). 
As demonstrated by the above studies, targeted gene replacement may facilitate to answer 
specific questions related to Leishmania virulence that can also potentially lead to elucidation of 
delicate differences between different Leishmania species. 
4.2 Proteophosphoglycans (PPGs) 
Since LPG was shown not to be the 'one and only' glycoconjugate that is essential for 
Leishmania virulence, recently the attention shifted to a novel class of highly glycosylated 
Leishmania glycocalyx components that emerge as key contributors to virulence, namely the 
proteophosphoglycans (PPGs). PPGs are a heterogeneous, rapidly expanding family of highly 
glycosylated Leishmania proteins that undergo extensive post-translational modification by 
phosphoglycan chains similar to those of LPG (Fig.5; reviewed in Ilg T, 2000b). Different 
Leishmania species show slightly diverse glycan structures on PPGs, similar to the species- and 
stage specificity described for LPG. Some PPGs in contrast, to LPG, are also expressed in the 
amastigote stage, which certainly entitles them being attractive candidate virulence factors of the 
intracellular stage in the invaded host cells. To date the novel class of PPGs has been most 
thoroughly studied in L. mexicana. 
Promastogote PPGs include secreted acid phosphatases (SAPs), filamentous PPG (fPPG), 
membrane bound GPI-anchored PPG (mPPG) and promastigote PPG2 (pPPG2), while amastigotes 
express mPPG and secrete large amounts of amastigote PPG (aPPG). 
SAPs exhibit a non-specific acid phosphatase activity and is released to the extracellular 
space via the flagellar pocket (Gottlieb M, 1982; Lovelace JK, 1986; Bates PA, 1989). L.mexicana 
secreted SAP is a complex comprising dominantly SAP1 (100 kDa) and minor amounts of SAP2 
(200 kDa), which are encoded by lmsapl and lmsap2 genes respectively (Ilg T, 1991a, b; Ilg T, 
2003). The two proteins are almost identical except for some Ser/Thr-rich repeats, however their 
phosphoglycan structures are reasonably different (Ilg T, 1993, 1994; Wiese M, 1995). The 
phosphoserine-linked glycan chains of SAP1 are rather short (15-20nm) and consist mostly a 1-2-
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oligomannoside caps with or without a single repeat unit, while those of SAP2 are longer (ca. 
lOOnm) phosphoglycans that are capped (Ilg T, 1994). The secreted SAP forms a millipede-like 
structure of remarkable length (2pm) via polymerization of subunits that can be well visualized by 
electron microscopy (Stierhof YD, 1998). In fact, the synthesis of polymerized SAP molecules is an 
enigma, since normally they are supposed to be assembled intracellularly in the Golgi apparatus. 
Instead of this rather unlikely scenario, the hypothesized place for the assembly of giant SAP 
macromolecule is the flagellar pocket, where they can reach an about 1000-fold higher 
concentration than in the medium that can well promote polymer formation (Stierhof YD, 1994). 
The function of SAPs is not well understood yet. The observation with L. mexicana that SAPs are 
not required for parasite growth or infectivity to macrophages and mice, implies that SAP function 
may be more important in the sandfly vector digestive tract, where via their low substrate specificity 
SAPs may have an important nutritional role (Ilg T, 1995,1999a; Wiese M, 1995,1998). 
fPPG is a filamentous heavily phosphoglycosylated (ca. 96% w/w of total weight) 6pm long 
macromolecule. Over half of its protein backbone made of Ser residues, in addition to Ala and Pro, 
and almost 90% of those are phosphoglycosylated with around three phosphodisaccharide-long 
repeats that are variably transferase-modified and capped at the end (Ilg T, 1999a). This composition 
of fPPG leads to a filamentous structure with a diameter of 3-6 nm that confers proteinase resistance 
to the macromolecule (Ilg T, 1999b). fPPG is secreted from the flagellar pocket of Leishmania 
promastigotes and based on its physicochemical properties is able to form a gel-like network 
(Stierhof YD, 1994). This mucin-like three-dimensional mesh or gel plug can obstruct the digestive 
tract of infected sandfly vector (Stierhof YD, 1999) and consequently can enhance the transmission 
of parasites via the regurgitation and multiple blood feeding (a mechanism also known as 'blocked 
fly hypothesis', Rogers ME, 2004). Although the role of fPPG in the mammalian host is less 
understood, it was shown that fPPG inhibits the production of tumor necrosis factor-alpha and 
synergizes with interferon-gamma to stimulate the production of nitric oxide by macrophages (Piani 
A, 1999). 
mPPG is a membrane bound PPG, attached via a GPI-anchor at the C-terminal domain (Ilg 
T, 1999a). Both promastigotes and amastigotes express mPPG, however the later ones do in much 
lower amounts (Piani A, 1999). The about 380 nm long protein chain encoded by the ppgl gene 
includes several Leu-rich repeat (LRR) homologous regions in the N-terminal domain, that are 
implicated in protein-protein interaction as well as modulating signal transduction, and numerous 
(ca. 100) acceptor sites for phosphoglycosylation (Ilg T, 1999a; Piani A, 1999). mPPG function is 
not well described yet, but its unique structure, its predominant expression in promastigote stage, 
and its phosphoglycan structures shared with LPG may allow us to consider some hypotheses. 
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Likely mPPG can far extend out from the promastigote gylcocalyx that makes this macromolecule 
highly exposed to the environment. This feature would dedicate mPPG to interact with sandfly 
midgut, macrophages, and complement components, such functions that were formerly uniquely 
attributed to LPG. Although the copy number of mPPG is much lower than that of LPG, but mPPG 
LRR domain interaction with complement receptor 3 (CR3) (Kedzierski L, 2004) and the presence 
of about 800 Ser-linked phosphoglycan chains for receptor or complement-binding, versus the single 
binding site carried by LPG, makes highly feasible that mPPG has a significant contribution to 
Leishmania infectivity. mPPG may also play a role in parasite attachment to macrophages and in the 
modulation of macrophage function at the early stage of infection (Piani A, 1999). 
Promastigotes secrete another PPG, the promastigote PPG2 (pPPG2) that is structurally 
distinct from SAP or fPPG/mPPG, but seems to share the same polypeptide backbone with a sereted 
amastigote PPG (aPPG) that both expressed from the ppg2 gene (Ilg T, 1995; Klein C, 1999). 
Although the polypeptide chain of 40-50nm length seems to be the same, its glycosylation appears 
to be stage-specific that can lead to remarkable differences in physicochemical properties and 
function between pPPG2 and aPPG (Klein C, 1999; Gopfert U, 1999). pPPG2 is glycosylated by 
either single capped monophosphorylated glycan or simple manno-oligosaccharides (Klein C, 
1999), while aPPG displays amastigote-specific highly branched glycan structures of six mono- or 
multiphosphorylated glycans with four oligosaccharide caps (Ilg T, 1998). The function of pPPG2 is 
still unknown, although several potential roles are assumed for aPPG. These include the inhibition 
of antigen presentation by the complex glycan chains, and assisting this way at parasite hiding from 
the host immune system. Furthermore, similarly to other polyanionic compounds, aPPG can lead to 
lysosome-like vacuolization in macrophages, and contributing this way to the formation of 
parasitophorous vacuoles. Morover, aPPG can deplete the host complement system via activating 
strongly the mannose-binding lectin pathway and consequently saving released amastigotes from 
potential complement lysis. 
It must be also noted that above functions of PPGs are partially inferred from the high 
similarity of their phosphoglycan motifs to other Leishmania glycoconjugates. 
4.3 Phosphoglycans (PGs) 
The supernatant of in vitro cultured Leishmania promastigotes * contains a hydrophilic 
phosphoglycan made of capped oligosaccharide repeat units identical to those found on LPG, but 
without the GPI anchor and the glycan core (Turco SJ, 1992). Their structure exclude the possibility 
of PI-PLC-mediated release from LPG. PGs, although their function is still elusive, were shown to 
be secreted from the flagellar pocket to the extracellular space (Ilg T, 1999b). 
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4.4 GPI-anchored proteins 
The glycocalyx of Leishmania promastigotes contains other abundant GPI-anchored 
proteins, than the formerly discussed mPPG, such as the major surface protease (MSP, also known 
as leishmanolysin or gp63), and the parasite surface antigen 2 (PSA-2)( Murray PJ, 1989). 
Leishmanolysin/gp63 is a highly conserved multigene family encoded 63-kDa zinc 
metalloproteinase that is GPI-anchored to the cell surface via a myristic acid containing anchor 
(Fig.5). This major cell surface glycoprotein of Leishmania promastigotes covers the entire cell with 
a copy number of 500,000 per cell that accounts for about 1% of total cellular proteins. In 
amastigote stage, leishmanolysin/gp63 lacks the GPI-anchor, and it is present at much lower levels 
and most of it localized to the flagellar pocket (Medina-Acosta E, 1989). Leishmanolysin/gp63 
contains three potential glycosylation sites (Button LL, 1988) that are N-glycosylated with high 
mannose-type biantennary glycan structures optionally with a 1,3 linked terminal glucose (Olafson 
RW, 1990 ; Funk VA, 1997). The two most common N-glycan structures found in promastogotes 
are Man6GlcNAc2 and GlcMan6GlcNAc2, while amastigote N-glycans are more variable. The 
importance of stage specific glycosylation, likewise the role of gp63 in parasite life cycle is not 
completely understood, although some functions were identified for gp63. These include, the 
proteolytic degradation of host macromolecules, protection from complement lysis, facilitating 
parasite binding to macrophages via complement components (Alexander J, 1992). Simultaneous 
targeted gene replacement for all genes of gp63 multigene family was not performed, although a 
recent study generated mutants lacking gp63 in an elegant way by simply knocking out GPI8, a GPI-
protein transaminidase that certainly led to the concomitant absence of other GPI-anchored proteins 
as well. Surprisingly these mutants grow normally, infectious to macrophages and mice, a finding 
that suggest that gp63 is not essential for Leishmania growth and infectivity (Hilley JD, 2000). 
Parasite surface antigen 2 (PSA-2) is an either membrane bound or secreted macromolecule 
that contains leucine-rich repeat (LRR) motifs, likewise PPG does. The first functional role of PSA-
2 has just been recently elucidated via hypothesizing parallel functions of PSA-2 and PPG based on 
their structural similarities (LRR motifs). In that study, Leishmania PSA-2 LRRs were shown also to 
bind to macrophages via CR3 (Kedzierski L, 2004). These findings prove that parasite attachment 
and invasion of macrophages involve a third Leishmania macromolecule, PSA-2, besides the better 
described PPGs and LPG. 
4.5 Glycoinositolphospholipids (GIPLs) 
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Free GPIs or GIPLs, are major low molecular weight glycolipid constituents of Leishmania 
glycocalyx that were shown to be expressed at nearly constant levels throughout Leishmania life 
cycle, in contrast to other major parasite glycoconjugates, such as LPG, PPGs, and GPI-anchored 
proteins that are strongly downregulated in amastigote stage (McConville MJ, 1993a, 1994; 
Beverley SM, 1996; Ferguson MA, 1999 and references therein). GIPLs are expressed on both 
promastigote and amastigote surfaces at very high copy numbers of about 107 molecules/parasite 
and are neither protein nor polysaccharide-bound (Fig.5). Classification of GIPLs is based on their 
glycan headgroups those may be structurally related to protein GPI anchors (type I GIPLs) with Man 
l,6Man l,4GlcN 1,6-PI structure, or to LPG anchors (type II GIPLs) with Man l,3Man l,4GlcN 
1,6-PI structure, or they can carry branched structures of the formerly mentioned ones based on a 
Man l,6(Man l,3)Man l,4GlcN 1,6-PI motif (hybrid type GIPLs). The lipid components of the 
hybrid and type I GIPLs are rich in alkyl-acyl-PI with shorter (CI8:0) alkyl chains, while type II 
GIPLs are more heterogeneous and contain longer alkyl chains (C24:0 or C26:0). The structure of 
different GIPLs is known in detail, however not that much is known about their function. Until 
recently, it was speculated that GIPLs are important virulence factors of the amastigote stage and 
believed to be involved in modulating signaling events in macrophages, such as NO synthesis and 
the oxidative burst. This notion was based on the observed abundant expression of GIPLs in 
amastogote stage, in contrast to other glycoconjugates. Additional observation that may support this 
hypothesis is that ectopic expression of T. brucei GPI-specific phospholipase C (GPI-PLC) in 
Leishmania leading to consequent depletion of GPI-anchored gp63, and several GIPLs, but not that 
of LPG, shows a phenotype exclusively in amastigotes that is characterized by reduced growth rate 
and infectivity to macrophages (Mensa-Wilmot K, 1994,1999). 
4.6 Lipid containing molecules acquired from the host 
Besides self-synthesized lipid containing molecules, Leishmania can acquire different host 
molecules, ranging from cholesterol to various complex glycoshingolipids that can make up 20% or 
50% of endogenous Leishmania pools, respectively. Resident host lipids in the lumen of 
parasitophorous vacuole may spontaneously intercalate into the amastigote plasma membrane or 
optionally after endocytosis and restructuring, being recycled to the plasma membrane. These host-
derived molecules may give additional advantage to the amastigotes for hiding from host defense 
mechanisms (Ginger ML, 1999, 2000, 2001; McConville MJ, 1991; Winter G, 1994; Tripathi A, 
2003; Schneider P, 1993; Puentes SM, 1988). 
4.7 N-linked glycans 
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Leishmania has an uncommon N-glycan structure of GlcMan6GlcNAc2 (Fig. 5), which has 
been most thoroughly studied in the GPI-anchored surface protease gp63. Our present knowledge 
about the role of N-glycans in Leishmania virulence or survival is rather limited. However, protein 
N-linked glycans are hypothesized to contribute to Leishmania virulence, based on the observation 
that tunicamycin-resistant Leishmania that has increased GlcNAc transferase activity due to gene 
amplification, loose their virulence more slowly and infect macrophages more efficiently than their 
wild type counterparts do (Kink JA, 1987). 
5. Rationales and aims of the study 
Cumulative evidence of large number of studies over the past 20 years suggests that 
mannose-containing glycoconjugates are required for Leishmania viability and virulence in every 
phase of their life cycle (Annex III. ref 1, 8, 10, and 17 and references therein). It is therefore 
surprising that the investigation of mannose activation pathway for glycoconjugate synthesis started 
only very recently. 
The structure and biosynthesis of Leishmania glycoconjugates has been thoroughly studied 
(Annex I. ref 2-6) and their glycan structures has been elucidated, which predominantly consists of 
repeating phosphodisaccharides of mannose and galacotose, and smaller amounts of GlcNAc, 
G1CNH2, Glc, D-Ara, and /wyo-inositol. These phosphoglycan structures seem to exhibit reasonable 
extent of structural and functional redundancy between different glycoconjugate classes. Therefore, 
one may hypothesize a special importance of given redundant glycan motifs instead that of single 
glycoconjugates of Leishmania. This notion is supported by experiences with LPG and gp63, and 
certainly raises questions about the rational of targeting simply particular virulence factors of 
Leishmania for dissecting its virulence (see section 4.1 Lipophosphoglycan (LPG)). 
The building blocks for the assembly of different glycan motifs are the activated nucleotide 
sugar donors, such as GDP-Man, Dol-P-Man, UDP-Gal, UDP-Glc, and GDP-D-Ara (Annex I. ref 6-
10). Given the high biosynthesis rate of the abundantly expressed glycoconjugates, the existence of 
a large and/or rapidly rechargeable pool of activated nucleotide sugar precursors can be assumed. 
Therefore, the mannose supply, which can be fueled from either external or internal sources, is 
predicted to have prime importance for Leishmania parasites. 
In yeast and in mammalian cells the activation of mannose from Man-6-P04 to GDP-Man or 
Dol-P-Man donors, requires the sequential enzymatic action of phosphomannomutase (PMM), 
GDP-mannose pyrophosphorylase (GDPMP), and Dol-P-Man synthase (DPMS). (Fig.6) Man-6-P04 
is a central metabolite in this pathway and may be supplied in two different ways. If exogenous Man 
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Fig.6. Schematic model of mannose activation pathway for Leishmania glycoconjugate biosynthesis. 
is available, it can be taken up by glucose transporters (Annex I. ref 11) or the more specific 
mannose transporter, and immediately phosphorylated by hexokinase to form Man-6-P04 (Fig.6; 
Annex I. ref 12). Alternatively, in the hexose-monophosphate pool, Frc-6-P04 can be converted to 
Man-6-P04 in a reaction catalyzed by phosphomannose isomerase (PMI) (Fig.6; Annex I. ref 13). 
The lack of the latter enzyme leads to a conditional lethal phenotype in yeast (Annex I. ref 14) and a 
severe metabolic disease in humans (Annex I. ref 15-17), which demonstrates the essential role of 
PMI for these organisms. Moreover, genetic deficiencies of the downstream members of this 
enzyme cascade, such as PMM, GDPMP or DPMS, were described leading to devastating, systemic 
disorders of humans that is caused mostly by a single allele deficiency (heterozygosity) of the gene 
encoding these enzymes (Jaeken J, 2001). Complete deficiencies of these enzymes in humans 
considered incompatible with life. 
Despite of its assumed central importance in glycoconjugate and glycan biosynthesis, the 
mannose activation pathway in Leishmania remained unexplored. However, its elucidation may 
have high scientific interest, especially in the context of identification of new potential drug targets 
for developing novel anti-parasitic medicines. 
Therefore, we dissected by reverse genetic tools via targeted gene replacement the enzyme 
cascade of mannose activation pathway in Leishmania mexicana as a model organism. This species 
was chosen, since the structures of their different glycoconjugates are very well described that 
allowed us the most detailed assessment. In our studies, we aimed to assess the impact of mannose 
V W 
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activation pathway on Leishmania viability, growth, glycoconjugate composition of glycocalyx, and 
the virulence of parasite with the expectation to identify potential drug targets. We also aimed to 
establish a relationship between glycoconjugate composition and virulence in Leishmania that may 
facilitate the development of vaccines for the control of leishmaniasis. 
6. Results and Discussion 
6.1 Elucidating the role of phosphomannose isomerase (PMI) in Leishmania 
mexicana 
Phosphomannose isomerase (PMI) catalyzes the reversible interconversion of fructose 6-
phosphate (Frc-6-PC>4) and mannose 6-phosphate (Man-6-P04), which is the first step in the 
biosynthesis of activated mannose donors required for the biosynthesis of various glycoconjugates 
(Fig.6). To investigate the role of PMI for parasite glycoconjugate synthesis, in Leishmania 
mexicana, the gene encoding PMI (Imexpmi) was cloned, and gene deletion mutants (Almexpmi) 
generated. The phenotype of Almexpmi mutants was characterized with emphasis on their viability, 
growth, glycoconjugate expression and virulence to macrophages and mice. 
6.1.1 Generation of L. mexicana mutants lacking PMI and characterization of 
their growth 
The gene, Imexpmi, encoding L. mexicana PMI was cloned based on homology to 
phosphomannose isomerase genes of other eukaryotic organisms including L. major, and sequenced, 
as a prerequisite of targeted gene replacement (Annex I., Fig. 2). The Imexpmi gene turned out to be 
present as a single copy gene in the genome of L. mexicana and was expressed at very similar levels 
in both promastigotes and amastigote stages (Annex I., Fig. 4A and B). Double-targeted replacement 
of Imexpmi gene was performed in L. mexicana promastigotes by state-of-art homologous 
recombination technology utilizing PCR amplified Imexpmi gene replacement cassettes (Annex I., 
Fig. 3). Surprisingly Almexpmi clones could be generated without additional mannose 
supplementation, in contrast to formerly identified auxotrophic yeast mutants (Payton MA, 1991). 
The absence of Imexpmi in L. mexicana Almexpmi mutants was confirmed by Southern blot (Annex 
I., Fig. 3B). Consistently, in L. mexicana Almexpmi mutants PMI enzyme activity could not be 
detected, while wide type parasites exhibited high PMI activity that even exceeded more than 15-
fold the mammalian PMI activities (Annex I., Fig. 4C, Annex I. ref 36), a level that is comparable to 
those found in the pathogenic fungi, C. albicans (75 milliunits/mg of protein, assay at 37 °C) (Annex 
I. ref 37). 
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For further experiments to characterize Almexpmi mutants, Imexpmi gene addback mutants 
were generated on Almexpmi mutant background with heterologous episomal expression vector 
(Almexpmi+pXlmexpmi) or alternatively with homologous recombination cassettes into the 
ribosomal locus (Almexpmi+pRSBlmexpmi) containing Imexpmi to show that the described features 
solely can be attributed to the lack of Imexpmi gene. 
In vitro cultured Almexpmi mutants were still able to multiply in standard growth medium, 
even when traces of Man were removed by extensive dialysis, although their growth was slower in 
comparison to wild type or Imexpmi addback (Almexpmi+pXlmexpmi) controls, a phenotype that 
could be reversed with exogenous mannose supplementation (0.2 mM)(Annex I., Fig. 5). It is 
surprising that in contrast to S. cerevisiae, Aspergillus nidulans, and C. albicans, wherein loss of 
PMI activity is lethal unless Man is provided, Almexpmi are viable and can multiply without 
exogenous mannose supply (Annex I. ref 14, 38, 39). Indeed this Almexpmi phenotype seems to be 
unique, because complete absence of PMI has never been observed in vertebrate cell lines. 
Moreover, only partial lack of PMI was observed in a human hereditary disease, termed congenital 
disorder of glycosylation (CDG) type lb that further strengthens the incompatibility of complete 
PMI absence with life (Annex I. ref 40). 
Additional experimental observations showed that further increase in mannose 
concentrations could progressively slow down the growth of Almexpmi mutants, while it did not 
affect control strains. This stress ultimately at a mannose concentration of lOmM led to killing of 
most Almexpmi parasites (Annex I., Fig. 5) that resembles to a phenomenon based on toxic 
accumulation of Man-6-P04 and possible ATP depletion, known as honeybee syndrome (Annex I. 
ref 41). 
6.1.2 L. mexicana Almexpmi mutants exhibit impaired glycoconjugate synthesis 
that can be reversed by exogenous mannose supplementation or Imexpmi gene 
addback 
Although PMI is not indispensable for Leishmania viability, its lack leads to profound 
changes in (phospho-)glycan content of Leishmania glycoconjugates that was shown in our studies 
by immunoblot, flow cytometry and immunofluorescence microscopy. 
Almexpmi promastigotes grown in standard medium were unable to synthesize 
phosphoglycan repeat-modified LPG and PPGs (Annex I., Fig. 6A lane 2-5, 6B, 7A, B, 8A-H), 
while L. mexicana Almexlpgl that are specifically defective in LPG synthesis (Annex I. ref 19), 
expressed still mPPG (Annex I., Fig. 6A lane 6). Despite the fact that LPG absence supposed to 
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increase the accessibility to the GPI-anchored leishmanolysin/gp63 on the surface of Leishmania, 
described in Almexlpgl and Almexlpg2 mutants (Annex I. ref 19, 32), the expression of this 
glycoprotein was decreased in Almexpmi mutants (Annex I., Fig. 7D). Furthermore, in Almexpmi 
mutants a general underglycosylation of glycoproteins were suggested by the decrease in surface 
binding sites for concanavalin A (Annex I., Fig. 7C, 8R), and by electrophoretic mobility shifts of 
many cellular proteins including secreted SAP (Annex I., Fig. 6C, D). Finally, the abundant 
promastigote GIPLs iM2, iM3, iM4, and EPiM3 (Annex I. ref 28) were down-regulated to 
undetectable levels (Annex I., Fig. 9), while metabolic [3H]G1CNH2 labeling revealed new, more 
hydrophobic GIPL species in Almexpmi mutants that were not seen in wild type controls. These 
novel GIPLs believed to represent precursors of GIPL biosynthesis, such as GlcNH2-
phosphatidylinositol or GlcNAc-phosphatidylinositol species. In contrast, to a recent observation 
that describes mannose-containing GIPLs as essential molecules for L. mexicana viability (Annex I. 
ref 42), Almexpmi mutants remained viable, while their mannose-containing GIPLs were 
downregulated to undetectable levels. 
The above-described phenotype of Almexpmi mutants can be restored by Imexpmi gene 
reexpression or exogenous mannose supplementation (200 pM) to the growth medium for bypassing 
the existing metabolic blockage, a fact reinforces that the observed phenotype can be attributed to 
the lack of Imexpmi gene. 
6.1.3 L. mexicana Almexpmi mutants are attenuated although remain infectious to 
macrophages and mice 
At last, the potential of Almexpmi mutants for infecting macrophages in vitro and developing 
lesions in mice in vivo was tested in a sensitive (Balb/c) mice strain. 
L. mexicana Almexpmi was less efficient in establishing and maintaining an infection in 
mouse peritoneal macrophages than the parental wild type strain (Annex I., Fig. 12A). The synthesis 
of phosphoglycan repeat epitopes by macrophage residing intracellular Almexpmi parasites was 
downregulated, but surprisingly still detectable, compared to wild type controls (Annex I., Fig. 13, 
compare E-H with A-D). 
In sensitive Balb/c mouse infection model, inoculation of L. mexicana Almexpmi into the 
footpad led to much smaller lesions compared to wild type parasites, but remarkably these mutants 
remained infectious (Annex I., Fig. 12B, C). 
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Episomal or, in particular, chromosomally integrated addback of the Imexpmi gene to 
Almexpmi mutants improved their ability to persist and multiply within macrophages and led to 
increased virulence to BALB/c mice (Annex I., Fig. 12). 
The fact that Almexpmi mutants, although severely attenuated, are still infectious to 
macrophages and mice is at first unexpected, because the general impairment of glycoconjugate 
synthesis (Annex I. ref 2), in particular the defect of GIPL assembly (Annex I. ref 43), supposed to 
preclude virulence completely. The remarkable observation although that in vitro cultured Almexpmi 
do not express phosphoglycan repeats (Annex I., Fig. 8B, F), unless exogenous mannose is 
supplemented, while macrophage internalized intracellularly residing Almexpmi do express them 
(Annex I., Fig. 13E-H), suggests that amastigotes must have access to host-derived mannose of 
unknown origin within the parasitophorous vacuole that may also be sufficient for remaining 
infectious. 
Taken together, this study shows that deletion of Imexpmi in L. mexicana leads to dramatic 
downregulation of glycoconjugate synthesis (the phosphoglycan repeats [-6-Gaipi-4Manal-P04-], 
the surface expression of the abundant GPI-anchored leishmanolysin, and GIPLs) and that 
surprisingly these mutants are viable, in contrast to a recent report (Annex I. ref 22). Moreover, 
Almexpmi mutants, although attenuated, remain infectious to macrophages and mice, a remarkable 
phenotype that likely can be attributed to a bypass of the glycosylation defect by host-derived 
mannose. 
The observation that Imexpmi is not indispensable for viability, implies that downstream 
disruption of mannose activation pathway to PMI may also be compatible with life. 
6.2 Elucidating the role of phosphomannomutase (PMM) in Leishmania mexicana 
Mammalian and fungal PMM catalyzes the reversible interconversion of Manal-P04 and 
Man-6-P04 (Fig.6). PMM requires Manal,6-bis-P04 as cofactor (Annex III. ref 32) and belongs to a 
novel family of phosphotransferases with its conserved DXDX(T/V) motif. The first aspartic acid in 
this sequence is involved in phosphate transfer and is transiently phosphorylated (Annex III. ref 4). 
S. cerevisiae PMM (Sec53p) was initially identified in a screen for mutations with defects in the 
secretory pathway (Annex III. ref 23). In humans, two enzymes (PMM1 and PMM2) with PMM 
activity have been cloned and characterized (Annex III. ref 27, 28). While PMM1 exhibits also a 
potent phosphoglucomutase activity, PMM2 is specific for Man-P04 and appears to be the dominant 
PMM in most human tissues (Annex III. ref 36). 
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To investigate the role of PMM in Leishmania, the Leishmania mexicana gene encoding 
PMM (Imexpmm) was cloned, and gene deletion mutants (Almexpmm) were attempted to be 
generated to characterize them phenotypically with emphasis on viability, growth, glycoconjugate 
expression and virulence to macrophages and mice. 
6.2.1 Generation and growth characteristics of L. mexicana mutants lacking 
PMM 
The Imexpmm gene, encoding L. mexicana PMM (LmxPMM), was homology cloned based 
on the sequence of other eukaryotic phosphomannomutases, and subsequently sequenced to perform 
targeted gene replacement of Imexpmm. Southern blot analysis of L. mexicana genomic DNA 
suggested that LmxPMM is a single copy gene (Annex III., Fig. 4A). RT-PCR revealed that 
LmxPMM mRNA is present in both parasite life stages but it is more abundant in mammalian host 
residing amastigotes (Annex III., Fig. 4B). However, the enzyme itself seems to be equally abundant 
in both life stages (Annex III., Fig. 5A) and largely (>95%) soluble in the cytosol (Annex III., Fig. 
5B), a finding that was also supported by immunofluorescence experiments (data not shown). 
Deletion of PMM gene in S. cerevisiae is lethal (Annex III. ref 23). Partial PMM2 deficiency 
in humans leads to the severe disease of congenital disorders of glycosylation (CDG) type la that is 
characterized by underglycosylation of many proteins and severe encephalopathy leading to 
psychomotor retardation (Annex III. ref 34). Remarkably, among hundreds of mutations, none has 
been identified that leads to complete abrogation of PMM2 activity, therefore complete lack of 
PMM is considered incompatible with human life. 
Surprisingly targeted gene replacement of Imexpmm was successfully performed in L. 
mexicana, and a series of PMM mutant clones (Almexpmm) was isolated (Annex III., Fig. 4A). The 
absence of LmxPMM was confirmed by immunoblotting total-cell lysates (Annex III., Fig. 4C). 
These clones were viable in standard culture medium and showed only a mild growth defect 
compared to wild type parasites that defect as expected could not be rescued by exogenous mannose 
supplementation (Annex III., Fig. 6C). 
In enzyme assays, Almexpmm mutants showed markedly lowered PMM enzyme activity, 
with less than 10% of wide type levels that likely derives from minor PMM activities of other 
mutases like phosphoglucomutase or phospho-N-acetylglucosaminemutase (Annex III., Fig. 6A). 
6.2.2 Overall downregulation of mannose-containing glycoproteins and 
glycolipids in L. mexicana Almexpmm mutants that can be reversed by Imexpmm 
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gene addback 
The product of LmxPMM, Manal-PC>4, is the substrate for GDP-Man formation that directly 
or indirectly is the sole mannose donor for glycoconjugate synthesis in Leishmania (Annex III. ref 
22 and references therein; Fig.6). Therefore, the lack of LmxPMM predicted to have broad effect on 
the synthesis of Leishmania glycoconjugates. 
Almexpmm mutants indeed downregulated completely or strongly LPG, the phosphoglycan 
caps and repeats of PPGs as shown by different methods with the anti-phosphodisaccharide repeat 
mAb LT6, anti-phosphotrisaccharide repeat mAb LT17, and anti-phosphoglycan cap mAb L7.25 
(Annex III., Fig. 4D-F, 7B, J,L). The lack of LPG was also confirmed by metabolic [3H]inositol 
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labeling, which experiment also shown absence of [ HJinositol-labeled GPI-anchored 
gp63/leishmanolysin (Annex III., Fig. 5C). Downregulation of gp63/leishmanolysin was also 
confirmed by surface labeling (Annex III., Fig. 7D, E, K), suggesting that protein GPI anchor 
synthesis was also severely affected in Almexpmm mutant parasites. The abundant GIPLs were 
undetectable in Almexpmm by HPTLC of total lipids with or without metabolic labelings, while 
some novel GIPLs seemed to appear (Annex III., Fig. 5E-H). The presence of N-glycosylation 
defect in Almexpmm mutants was evidenced by mobility shift of the normally heavily N-
glycosylated MBAP (Annex III., Fig. 5D; Annex III. ref 31, 41). Fluorescence microscopy and 
FACS showed extremely weak signal in Almexpmm with ConA (Fig. 7G, H, M), a lectin that 
strongly binds to a-Man residues (Annex III. ref 7) present in L. mexicana N-glycans, LPG, PPGs, 
and GIPLs (Annex III. ref 8, 16, 17, 21), a finding that suggests an overall downregulation of 
mannose-containung glycoconjugates. Hexose analysis by sensitive gas chromatography-mass 
spectrometry confirmed this observation, since the amount of macromolecule-associated mannose 
(all known lipid- and protein-bound mannose-containing glycoconjugates) in Almexpmm mutants 
was below the detection limit (less than 1% of wild-type levels)( Annex III., Fig. 6D). 
The low-level expression of GPI-anchored gp63, mannooligosaccharide caps, and ConA 
binding sites in Almexpmm mutants assayed by sensitive immunochemical techniques and lectin 
binding, may be explained by the leakiness of mutants attributed to the detected minimal PMM 
activity of other enzymes that may lead to synthesis of very limited amounts of Manal-P04. 
The glycosylation defects of Almexpmm can be reversed by Imexpmm gene addback, but in 
contrast to the PMI mutants, this phenotype cannot be rescued by exogenous mannose (Annex III., 
Fig. 4A, C-F, 5C, D, H, 6C, 7C, F, I, J-M). 
6.2.3 Loss of virulence phenotype of L. mexicana Almexpmm mutants to 
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macrophages or mice 
Almexpmm mutant promastigotes were unable to establish an infection in cultured 
macrophages (Annex III., Fig. 11 A), which cannot be attributed to lack of attachment to or that of 
host cell invasion, because they were as efficiently taken up by macrophages as wild type 
counterparts, however Almexpmm mutants were eliminated soon after (not shown). 
Furthermore, Almexpmm promastigotes proved to be avirulent to sensitive Balb/c mice, even 
at high parasite load (107/mouse) (Annex III., Fig. I IB, C). Attempts to reisolate Almexpmm 
parasites from inoculated animals were repeatedly unsuccessful, suggesting that the parasites cannot 
establish an asymptomatically persisting infection in vivo. Wild type level of virulence for 
Almexpmm mutants could be restored by Imexpmm gene addback either by chromosomal integration 
into the rRNA locus or by episome (Annex III., Fig. 11 A, B, and C). 
The loss of virulence may be explained by the inability of Almexpmm parasites to utilize 
exogenous mannose from host derived source for glycoconjugate synthesis, in contrast to Almexpmi 
parasites that retained this capacity and consequently their virulence (Annex III. ref 11). 
The unique observation that Imexpmm is not indispensable for viability, implies that 
downstream disruption of mannose activation pathway to PMM could also be compatible with life. 
Therefore, we decided to dissect further the mannose activation pathway in L. mexicana, namely to 
study the GDP-mannose pyrophosphorylase (GDPMP) enzyme. 
6.3 Studying the role of GDP-mannose pyrophosphorylase (GDPMP) in 
Leishmania mexicana 
The consecutive action of phosphomannomutase (PMM) and GDP-mannose 
pyrophosphorylase (GDPMP) transforms the exogenous or hexomonophosphate pool-derived Man-
6-PO4 to GDP-Man, which is a key nucleotide sugar of mannose activation pathway that feeds the 
eukaryotic glycoconjugate synthesis (Fig.6; reviewed in Annex II. ref Freeze H, 1999). GDP-Man is 
the directly or indirectly utilized mannose donor for all mannosylation reactions in eukaryotes, 
moreover a precursor of GDP-fucose synthesis (Annex II. ref Kaufman RL, 1968) and substrate of 
ascorbic acid synthesis in plants (Annex II. ref Wheeler GL, 1998). The essential role of GDP-Man 
is supported by the observations describing a lethal phenotype of Saccharomyces cerevisiae and 
Candida albicans, when their genes encoding GDPMP, or other members of mannose activation 
pathway, are deleted (Annex II. ref Hashimoto H, 1997; Warit S, 2000; Kepes F, 1988; Orlean P, 
1988). To date, no uni- or multicellular eukaryotic organisms were reported with complete absence 
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of GDPMP activity that suggests that complete disruption of the mannose activation pathway and 
the resulting absence of mannose-containing glycoconjugates are incompatible with eukaryotic life. 
On the other hand, our observations in Leishmania, when almost abolished PMM enzyme 
activity (Almexpmm) was still compatible with life, although insufficient for maintaining the 
biosynthesis of mannose-containing glycoconjugates, suggested that in contrast to other eukaryotes 
and a recent report on the essential need of Dol-P-mannose in Leishmania (Annex III. ref 22), the 
lack of GDPMP may be compatible with life. 
To test our hypothesis about of GDPMP in Leishmania, the gene encoding GDPMP 
(Imexgdpmp) was cloned, and gene deletion mutants (Almexgdpmp) were intended to be generated, 
with the hope to find a unique eukaryotic phenotype that can be characterized with special emphasis 
on viability, growth, glycoconjugate expression and in these parasites also for virulence. 
6.3.1 Attempt to generate L. mexicana mutants lacking GDPMP 
The Imexgdpmp gene, encoding L. mexicana GDPMP (LmxGDPMP), was homology cloned 
based on the sequences of other eukaryotic GDPMPs (Annex II., Fig. IB). 
Northern blotting and RT-PCR analysis suggest that LmxGDPMP mRNA is present in both 
parasite life stages, and somewhat more abundant in the intracellular amastigote forms (Annex II., 
Fig. 2D, E), although immunoblots of total cell lysates probed with affinity-purified antibodies 
against recombinant LmxGDPMP indicate equal abundance of LmxGDPMP in both life stages 
(Annex II., Fig. 3D). LmxGDPMP activity is largely (>90%) soluble (data not shown), which is in 
agreement with immunoblotting studies on membrane fractions (Annex II., Fig. 3E). 
Immunofluorescence experiments on permeabilized promastigotes using anti-LmxGDPMP serum 
gave a diffuse signal throughout the cell body, which is also in alignment with a cytoplasmic 
localization of LmxGDPMP (Annex II., Fig. 5C). 
The single-copy Imexgdpmp was attempted to be knocked-out by targeted gene replacement, 
which was described to give rise lethal phenotype in Saccharomyces cerevisiae and Candida 
albicans. 
Surprisingly, two rounds of targeted Imexgdpmp gene replacement using the antibiotic 
resistance markers HYG (hygromycin) and BLE (bleomycin) in L. mexicana, a eukaryotic organism, 
(Annex II., Fig. 2A) gave rise clones lacking both alleles of Imexgdpmp (Almexgdpmp)(Annex II., 
Fig. 2C) and the protein LmxGDPMP as well (Annex II., Fig. 3A). Therefore, remarkably in 
Leishmania the complete absence of GDPMP encoding gene, in contrast to other eukaryotes, results 
in viable mutants that showed only a mild mannose independent growth defect (Annex II., Fig. 4H). 
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Although LmxGDPMP is largely cytoplasm located, GDPMP enzyme assays gave strong 
GDP-Man-independent background reactions, probably due to different metabolites and/or enzymes 
present in crude extracts. Therefore, to compare LmxGDPMP activity in wild type and Almexgdpmp 
mutants, concentrated ultracentrifugation supernatants were fractionated by gel filtration to remove 
interfering components. While in wild type fractions, a prominent LmxGDPMP activity peaked 
between 240 and 300 kDa, no LmxGDPMP activity could be detected in Almexgdpmp mutants 
(Annex II., Fig. 4A). Determination of UDP-glucose pyrophosphorylase (UDPGP) enzyme activity 
in both chromatography runs served as control for equivalent loadings (Annex II., Figure 4A). 
6.3.2 Overall downregulation of mannose-containing glycoproteins and 
glycolipids in L. mexicana Almexgdpmp mutants 
Earlier studies suggested that in L. mexicana, like in other eukaryotes, GDP-Man is the sole 
mannose donor for glycoconjugate synthesis (Fig.6; Annex II. ref Mengeling BJ, 1997; Ilgoutz SC, 
1999; Moss JM, 1999 and references therein). Therefore, in agreement with the foreseen impact of 
mannose activation pathway blockage for glycoconjugate synthesis, Almexgdpmp mutants do not 
express any of the known lipid- and protein-bound mannose-containing glycoconjugates. The 
Almexgdpmp phenotype was described applying different techniques including immunoblotting, 
immunofluorescence microscopy, FACS and metabolic labeling with radioactively labeled 
metabolites, and showed the following characteristics: 
(I) absence of LPG and phosphodisaccharide glycan motifs on PPGs (Annex II., Fig. 3B, C, 
5A I vs. II, V vs. VI, 5B LT6 and LT17) and also complete lack of anti-phosphoglycan caps shown 
by mAb L7.25 (Annex II., Fig. 4E), moreover the normally highly phosphoglycosylated secreted 
acid phosphatase (SAP) showed a strong mobility shift detected by affinity purified anti-SAP 
antibody, which cannot be reversed by exogenous mannose (Annex II., Fig. 4D, F and G). 
(II) absence of the dominant GPI-anchored surface protein gp63 (Annex II., Fig. 5A, IX, X), 
although it could be detected within permeabilized cells, particularly in the perinuclear region, 
which suggested its retention in the endoplasmic reticulum for quality control reasons (Figure 5A, 
XI). Furthermore, the cross-reactive determinant (CRD), which is indicative of GPI-anchored 
proteins in many eukaryotes, including L. mexicana (Annex II. ref Zamze SE, 1988; Ilg T, 1993), 
was not present in GDPMP promastigote total cell lysates after GPI-phospholipase C (GPI-PLC) 
digestion (Annex II., Fig. 3G, lanes 3 and 4), and no [3H]inositol-labeled gp63 was detected after 
metabolic labeling (Annex II., Fig. 4C), suggesting that protein GPI anchor synthesis is severely 
downregulated in the mutant parasites. 
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(III) defect in N-glycosylation shown by the strong mobility shift (15-20 kDa) of the 
normally heavily N-glycosylated, but neither GPI-anchored nor phosphoglycosylated, membrane-
bound acid phosphatase (MBAP) (Annex II. ref Menz B, 1991; Wiese M, 1996) (Annex II., Fig. 3F, 
lanes 1 and 2). 
(IV) undetectable level of mannose-containing GIPLs examined either by orcinol staining or 
fluorography after metabolic labeling with [3H]Man, [ 3 H]G1CNH2 and [3H]myo-inositol in high-
performance thin-layer chromatography (HPTLC)-separated total lipids (Annex II., Fig. 6). 
(V) general lack of a-Man residues shown by the absent signal for the strong a-Man binding 
lectin, concanavalin A (ConA) by fluorescence microscopy or FACS analysis that suppose to detect 
Lmexicana N-glycans, LPG, PPGs and GIPLs (Annex II. ref Ilgoutz SC, 1999; Ilg T, 2000a,b; Ilg 
T, 2001) (Annex II., Fig. 5A, XIII, XIV, and B ConA). 
(VI) finally, hexose analysis of trifluoroacetic acid (TFA)-hydrolyzed promastigote 
membranes by high-pH anion-exchange high-pressure liquid chromatography (HPLC) showed that 
Man is absent (<1%) in macromolecules (Annex II., Fig. 4B), a result also confirmed by hexose 
analysis using gas chromatography-mass spectrometry (<0.5% of wild-type levels; A.Garami, T.Ilg, 
A.Mehlert and M.A.J.Ferguson, unpublished results). 
The fact that the above described Almexgdpmp mutant phenotype with profound 
glycosylation defects could be reversed by Imexgdpmp gene addback (Annex II., Fig. 2B and C) -
leading to reconstitution of all glycoconjugates investigated in this study (Annex II., Fig. 3A-C, F, 
lanes 3; 3G, lanes 5, 6; 5A, IV, VIII, XII, XVI, B), although the re-expressed enzyme level was only 
-10-20% of the wild-type levels (Annex II., Fig. 3A and data not shown) - suggests that the 
Almexgdpmp mutant phenotype was caused by the absence of Imexgdpmp gene. 
6.3.3 Loss of virulence phenotype of L. mexicana Almexgdpmp mutants to 
macrophages or mice 
Almexgdpmp mutant promastigotes were totally unable to establish an infection in cultured 
macrophages (Annex II., Fig. 7A). This was not due to the lack of attachment or that of host cells 
invasion, as demonstrated by time course experiments, wherein the Almexgdpmp mutants after 
internalization were rapidly killed, whereas wild-type parasites survived (Annex II., Fig. 7B) and 
proliferated (data not shown). 
Furthermore, L. mexicana Almexgdpmp promastigotes proved to be completely avirulent to 
Balb/c mice, even at a high parasite load (1 x 107/mouse) (Annex II., Fig. 7C, D). Moreover, the 
repeated attempt to re-isolate GDPMP parasites from the site of injection, the draining lymph nodes 
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or the spleen of challenged animals was unsuccessful that suggests the absence of persisting 
parasites. 
Virulence of Almexgdpmp mutants to both, macrophages and mice, could be completely 
restored by Imexgdpmp gene reexpression (episomal or rRNA locus integrated) (Annex II., Fig. 7A, 
C and D). 
Uniquely, this work is the first demonstration of a viable eukaryotic organism with complete 
disruption of mannose activation pathway and the concomitant loss of all known mannose-
containing glycoconjugates. Almexgdpmp mutants downregulate LPG, PPGs, mannose-containing 
GIPLs, GPI-anchored proteins and mannose-containing N-glycans to levels undetectable by 
different sensitive methods. In Almexgdpmp mutants, LmxGDPMP activity is undetectable, and no 
evidence supports the existence of an alternative pathway for GDP-Man synthesis. If such a 
hypothetical pathway would exists in L.mexicana, it must be extremely inefficient. 
Taken together, the exclusive observation that Imexgdpmp is not indispensable for 
Leishmania viability, when no traces of LmxGDPMP enzyme activity could be detected, in contrast 
to the slightly 'leaky' Almexpmm mutants, strongly suggests that downstream disruption of mannose 
activation pathway should also be compatible with life. Therefore, in contrast to a recent report in Z,. 
mexicana (Annex III. ref 22), the deletion of dolicholphosphate-mannose synthase gene (Imexdpms) 
would be expected to give rise viable parasites with largely unaffected biosynthesis of PPGs and N-
glycan structures (Fig.5). 
To test our hypothesis the role of dolicholphosphate-mannose synthase (DPMS) was studied 
in L. mexicana. 
6.4 The role of dolicholphosphate-mannose synthase (DPMS) in Leishmania 
mexicana 
DPMS is an endoplasmic reticulum associated enzyme that catalyzes the formation of 
dolicholphosphate-mannose (Dol-P-Man), the second major activated mannose donor for 
glycosylation reactions (Fig.6). Two different types of DPMS exist in eukaryotes: the enzymes of S. 
cerevisiae, Trypanosoma brucei, and Leishmania mexicana are formed by a single polypeptide 
chain, while DPMS from mammals, worms, and Schizosaccharomyces pombe is composed of three 
subunits (Annex III. ref 26). Mutation in human DPMS leads to congenital disorders of 
glycosylation (CDGs) type Ie, which is characterized by underglycosylation of many proteins and 
severe encephalopathy leading to psychomotor retardation (Annex III. ref 34). Remarkably, in CDG 
type Ie cases, a residual DPMS activity is always detectable, therefore the complete lack of DPMS is 
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considered to be incompatible with human life (Annex III. ref 37), just as a report suggested it for L. 
mexicana (Annex III. ref 22). 
6.4.1 Attempt to generate L. mexicana mutants lacking DPMS 
DPMS is an essential enzyme for S. cerevisiae (Annex III. ref 33) and S. pombe (Annex III. 
ref 5). The gene encoding L. mexicana DPMS (Imexdpms) has recently been cloned and sequenced, 
and it has been reported that this enzyme is essential for L. mexicana (Annex III. ref 22). However, 
the successful generation of L. mexicana PMI, PMM, and GDPMP gene deletion mutants led us to 
the conclusion that in contrast to this previous report, LmxDPMS may also not be required for L. 
mexicana viability. 
In agreement with this notion, after cloning the locus of L. mexicana single-copy DPMS 
gene by PCR amplification, two rounds of targeted gene replacement (Annex III., Fig. 3A) resulted 
in parasite clones lacking both alleles of LmxDPMS ORF (Almexdpms) (Annex III., Fig. 8A). In 
Almexdpms promastigotes, the 29-kDa LmxDPMS protein band was no longer detectable (Annex 
III., Fig. 8C). To assess DPMS activity of Almexdpms mutants, [14C]Man transfer from GDP-
[14C]Man into the lipid fraction of resuspended microsomal pellets was measured that showed a lack 
of signal for Almexdpms mutants in comparison to wild type controls (Annex III., Fig. 6B). 
Immunoblottings on subcellular fractions showed that LmxDPMS is likely a membrane-associated 
protein (Annex III., Fig. 9B), as it was also predicted by its DNA sequence (PMMref22). LmxDPMS 
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mRNA appeared to be expressed at higher levels in amastigotes, while its protein product showed 
higher levels in promastigote stage (Annex III., Fig. 8B, 9A). 
6.4.2 Downregulation of selected mannose-containing glycoproteins and 
glycolipids in L. mexicana Almexdpms mutants 
In vitro studies on microsome fractions suggested that Dol-P-Man is the a-mannose donor 
for the following glycoconjugates in L. mexicana: the first mannose residue of LPG core sequence, 
all three mannose residues of protein GPI anchors, the first two mannose of GIPLs, and possibly the 
sixth mannose (Man6) of N-glycans. By contrast, the biosynthesis of phosphoglycan chains on both 
LPG and PPGs and the synthesis of Man 1-5 of N-glycans require exclusively GDP-Man, so does 
not depend on Dol-P-Man (Fig.6 and 7; also Annex III., Fig. 1 A, B; Annex III. ref 22). 
In agreement with the above model, the Almexdpms mutants showed the following 
phenotype: 
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(I) lack LPG, as indicated by immunoblots (Annex III., Fig. 8D, E), metabolic labeling with 
[3H]myo-inositol (Annex III., Fig. 9C), immunofluorescence microscopy with MAb LT6 (Annex 
III., Fig. 10A, B, B'- the secretory organelle located weak signal appearing at longer exposure is 
most likely due to the secretion of phosphoglycosylated SAP and fPPG (Annex III. ref 39), whose 
glycosylation is not affected by the lack of LmxDPMS), and by unsuccessful attempts of purifying 
LPG by standard methods (not shown) (Annex III. ref 29). 
(II) the phosphoglycan repeat and mannooligosaccharide cap synthesis of proteins, in 
contrast to LPG, remains normal or is even slightly elevated, as shown by immunoblottings of total-
cell lysates (Annex III., Fig. 8D-F) or culture supernatant containing the major secreted PPGs, SAP 
and fPPG (data not shown). 
(III) the biosynthesis of GPI anchors defective in the mutants, shown by undetectable surface 
expression of the GPI-anchored metalloproteinase gp63/leishmanolysin (Annex III., Fig. 10D, E, 
10K), and the lack of [ HJmyo-inositol label incorporation into gp63 or any other Leishmania 
proteins (Annex III., Fig. 9C, lanes 1 and 2). The intracellular staining that appears in permeabilized 
Almexdpms mutants (Annex III., Fig. 10E') suggests an endoplasmic reticulum localization of gp63 
and may reflect the blockage of its intracellular trafficking because of insufficient GPI-anchor 
linkage. 
(IV) N-glycosylation does not seem to be greatly affected, since no significant 
electrophoretic mobility shift of the heavily N-glycosylated, although not phosphoglycosylated or 
GPI-anchored (Annex III. ref 31) membrane-bound acid phosphatase (MBAP), was observed 
(Annex III., Fig. 9D, lanes 1 and 2). Moreover, ConA surface binding was comparable in 
Almexdpms and wild-type promastigotes, as indicated by immunofluorescence microscopy (Annex 
III., Fig. 10G, H) and FACS analysis (Annex III., Fig. 10M). 
(V) dominant Man-containing GIPLs iM2, iM3, and iM4 of wild-type parasites (Annex III. 
ref 30) are absent in Almexdpms promastigotes by orcinol staining of HPTLC-separated total lipids 
(Annex III., Fig. 9E, lane 1, 2) that was confirmed by [3H]Man, [ 3 H]G1CNH2 (Annex III., Fig. 9F 
and G), and [3H]myo-inositol (not shown) labelings. 
(VI) hexose analysis by gas chromatography-mass spectrometry confirmed that the total 
mannose content of Almexdpms promastigote membranes is rather low, was only around 3% in 
comparison to wild type parasites (Annex III., Fig. 6D). 
Reexpression of Imexdpms gene either by chromosomal integration into the ribosomal locus 
(Annex III., Fig. 3B, 8A, C-F lanes 3, 9C-G lanes 3, 10C, F, I, J-M) or introduction of episomal 
gene copies (Annex III., Fig. 10L and data not shown) led to reversion of the described 
glycosylation defects of LPG, protein GPI anchors, and GIPLs in A Imexdpms. 
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6.4.3 Attenuated virulence phenotype of L. mexicana Almexdpms mutants to 
macrophages or mice 
Although L. mexicana Almexdpms mutants lack LPG, GPI-anchored gp63 and mannose-
containing GIPLs, unexpectedly still succeeded in colonizing host cells and showed only moderate 
decrease in infectivity to macrophages in comparison to wild type controls (Annex III., Fig. 1 ID). In 
Balb/c mice, the onset and progression of disease caused by Almexdpms was only marginally slower 
in comparison to the wild-type control strain, but eventually the animals failed to control the 
infection (Annex III., Fig. 11E). Almexdpms parasites could be reisolated from lesion tissue, 
draining lymph nodes and the spleen of inoculated animals, which confirms the in vivo persistence 
of Almexdpms mutants. The decrease in infectivity to macrophages and virulence to mice could be 
completely rescued by reexpression of Imexdpms gene (Annex III., Fig. 1 ID and E). 
LmxDPMS has been reported to be essential for Leishmania (Annex III. ref 22). In contrast 
to this view, the existence of L. mexicana mutants that lack upstream key members (LmxPMM and 
LmxGDPMP) of mannose activation pathway suggested that, LmxDPMS should not be required for 
L. mexicana viability either. The successful generation of knockout parasites that lack Imexdpms 
when lacking DPMS activity, has proven this assumption. Unexpectedly, these mutants although 
lacking glycoconjugates that were described earlier on as major virulence factors (Annex III. ref 3, 
8, 38), such as, LPG, Man-containing GIPLs, and the GPI-anchored surface metalloproteinase 
leishmanolysin (gp63), still remain infectious to macrophages and mice. 
Taken together, the above observations indeed call for revisiting the role of Leishmania 
glycoconjugate virulence factors. 
7. Conclusion 
Solid body of evidence based on large number of studies over the past 20 years suggests that 
mannose-containing glycoconjugates are required for Leishmania viability and virulence throughout 
their life cycle (Annex III. ref 1,8,10, and 17 and references therein). The glycan structures of these 
Leishmania glycoconjugates predominantly consists of mannose and galacotose, and smaller 
amounts of GlcNAc, GlcNH2, Glc, D-Ara, and wyo-inositol. The building blocks for glycoconjugate 
biosynthesis are various activated nucleotide sugar donors, such as GDP-Man, Dol-P-Man, UDP-
Gal, UDP-Glc, and GDP-D-Ara (Annex I. ref 6-10). Given the high rate of glycoconjugate synthesis 
in Leishmania, the proper mannose supply is predicted to be prime importance for these parasites. 
Therefore, our studies tried to elucidate the importance of mannose activation pathway by dissecting 
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it via reverse genetics, and estimate the role that of for Leishmania viability, growth, glycoconjugate 
virulence factor synthesis, and virulence that eventually may lead to potential novel treatments of 
leishmaniasis. 
The mannose activation pathway that is well described in yeast and mammalian cells and 
generates GDP-Man and Dol-P-Man donors for glycosylation, requires the sequential enzymatic 
action of phosphomannose isomerase (PMI), phosphomannomutase (PMM), GDP-mannose 
pyrophosphorylase (GDPMP), and Dol-P-Man synthase (DPMS). Partial deficiency of any enzymes 
on this cascade were described as devastating genetic disorders of humans, moreover complete loss 
of enzyme function is considered being incompatible with life. 
In our studies in Leishmania mexicana - as one of the best-studied model species of 
Leishmania for glycoconjugate composition, synthesis, and structure - the genes of mannose 
activation pathway were homology cloned and sequenced with the aim to generate stepwise mutants 
lacking members of this enzyme cascade at different levels. 
Remarkably, in contrast to different pathogenic fungi, yeast species or humans, - wherein 
functional lack of mannose activation pathway, leading to lack of glycoconjugates, is incompatible 
with life - in Leishmania, targeted gene deletion mutants were generated successfully without major 
difficulties and they turned out to be viable without traces of mannose supplementation to the 
medium. These results doubtlessly show that mannose-containing glycoconjugates, in contrast to a 
former report in L. mexicana (Annex II. ref Ilgoutz SC, 1999), are not essential for Leishmania 
viability, although the in vitro growth of mutants was slightly affected. In the case of Almexpmi 
mutants, this growth phenotype can also be reversed to normal by exogenous mannose 
supplementation, which confirms that Leishmania, likewise other eukaryotes, also can have 
mannose from two sources, an internal one from the hexose-monophosphate pool or external uptake 
via mannose transporter, in line with our current understanding of the mannose activation pathway 
(Fig.6). 
As it was anticipated, the mutants lacking components of mannose activation pathway show 
complex phenotype in terms of surface glycoconjugates and virulence (Table 1). 
The deletion of Imexpmi leads to dramatic downregulation of glycoconjugate synthesis, 
namely LPG, the phosphoglycan repeats [-6-Gaipi-4Manal-P04-] of PPGs, the surface expression 
of GPI-anchored gp63/leishmanolysin, and mannose-containing GIPLs, that can be reversed to 
normal by exogenous mannose supplementation. 
The phenotype of Imexpmm knockout mutants was more remarkable, wherein the absence of 
Imexpmm leads to striking lack of protein and lipid glycosylation to such an extent that the mannose 
content of the membranes is undetectable (less than 1% of wild-type levels). Furthermore, mannose-
43 
PMI PMM GDPMP DPMS 
Frc-6-PO, — • Man-6-PO,—• Mana-1 -P04 — • GDP-Man Dol-P-Man 
L. mex. 
strain 
wild type APMI APMM AGDPMP ADPMS ALPG1 ALPG2 AGPI18 
LPG norm 0 0 0 0 0 0 norm 
Glyc. of 
PPGs 
norm 0 or 
m 
0 0 norm norm 0 norm 
GPI-
anchored 
proteins 
(gp63) 
norm u 0 or III 
0 0 norm norm 0 
Mannose 
cont. 
GIPLs 
norm 0 0 0 0 norm norm norm 
N-
glycans 
norm M 0 or m 
0 norm or 
<*> 
norm norm norm 
virulence + + + + - - ++ + + + +++ +++ 
reference several Garami 
and llg, 
2001 
JBC 
Garami 
et al., 
2001 Mol 
Cell Biol 
Garami 
and llg, 
2001 
EMBO J 
Garami 
et al„ 
2001 Mol 
Cell Biol 
llg, 2000 
EMBO J 
llg et al., 
2000 
JBC 
Hilley et 
al., 2000 
Mol Biol 
Cell 
Table. 1. Glycosylation defects and virulence phenotype of L. mexicana mutants. 
containing GIPL expression is also undetectable by radiolabeling techniques. Only sensitive 
immunochemical techniques and lectin binding assays detect low level expression of GPI-anchored 
gp63, mannooligosaccharide caps, and ConA binding sites in Almexpmm mutants. This slight 
leakiness of Almexpmm parasites may be explained by the synthesis of very limited amounts of 
Manal-P04 via some residual PMM activity that may be attributed to other mutases, such as 
phosphoglucomutase or phospho-N-acetylglucosaminemutase. 
The lack of next enzyme in the sequence, LmxGDPMP, leads to an even more remarkable 
phenotype characterized by the downregulation of all mannose-containing glycoproteins and 
glycolipids, such as LPG, PPGs, GPI-anchored proteins (gp63), mannose-containing GIPLs and N-
glycans to undetectable levels. This work notably is the first demonstration of a viable eukaryotic 
organism with the complete disruption of mannose activation pathway and consequent loss of all 
known mannose-containing glycoconjugates. It must also be mentioned that at present, there is no 
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evidence for the existence of any alternative pathway for GDP-Man synthesis, and even if such a 
hypothetical pathway might exist in L. mexicana, it must be extremely inefficient. 
Almexdpms mutants, lacking LmxDPMS, exhibit a complex phenotype described by selective 
lack of LPG, mannose-containing GIPLs, and the GPI-anchored leishmanolysin (gp63) that all have 
been described as major virulence factors in Leishmania (Annex III. ref 3, 8, 38), while N-
glycosylation appears to be largely unaffected. 
The virulence of all mannose activation pathway mutants to macrophages in vitro or to mice 
in vivo was affected, however to different extent. The Almexpmi and Almexdpms mutants remain 
infectious, although are attenuated, while Almexpmm and Almexgdpmp mutants appear to be 
avirulent. 
The fact that the Almexpmi mutants, although severely attenuated, are still infectious, most 
probably can be attributed to a bypass of the glycosylation defect supplied by host-derived mannose. 
Furthermore, in contrast to Almexpmi mutants, the inability of Almexpmm and Almexgdpmp 
parasites to utilize exogenous mannose could be an explanation of their avirulent phenotype. 
Based on recent data and the studies summarized in this thesis that apply L. mexicana as a 
model system, a comprehensive picture about the role and significance of mannose-containing 
glycoconjugates in Leishmania virulence is emerging (Table 1): we have shown earlier that LPG 
alone is not required for full virulence of L. mexicana (Annex III. ref 16). The absence of GPI-
anchored proteins, including gp63 (Annex III. ref 15), and the lack of LPG and PPGs (Annex III. ref 
21) is not abrogating virulence to mammals either. In Almexpmi mutants, although in vitro several 
mannose-containing glycoconjugates (LPG, phosphoglycan repeats of PPGs, GPI-anchored gp63 
and mannose-containing GIPLs) are strongly downregulated, in vivo they remain infectious, but 
attenuated, because of a bypass effect by host-derived mannose that enables the invading parasites to 
reconstitute their surface molecules almost equivalent to that of wild-type levels. Even combined 
absence of LPG, GPI-anchored gp63, and mannose-containing GIPLs, as it was shown in L. 
mexicana Almexdpms mutants, does not lead to loss of virulence, only attenuation of these parasites. 
However, severe downregulation or absence of all mannose-containing glycoconjugates in 
Almexpmm or Almexgdpmp mutants, respectively, renders Leishmania unable to infect macrophages 
and mice. 
The open question that remains after all: What are than the essential glycan components 
required for virulence? In contrast to the avirulent Almexpmm or Almexgdpmp mutants, the virulent 
Almexdpms parasites have normal capacity to synthesize PPG phosphoglycan repeats and caps, and 
their N-glycosylation appears to be largely unaffected. This fact nominates these moleci1 
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candidates responsible for Leishmania virulence. On the other hand, the virulent lmexlpg2 mutants 
lack phosphoglycans on PPGs, except for a small numbers of mannooligosaccharide cap epitopes 
(Table 1) (Annex III. ref 21). This leaves the latter structures and N-glycans on the agenda as 
potential determinants of Leishmania virulence. 
Alternatively, it is conceivable that between the five different classes of Leishmania 
glycoconjugates (LPG, PPGs, protein GPIs, GIPLs, and N-glycans) a shared functional redundancy 
may exist in their contribution to virulence. Certainly, this would allow the parasites to lack one, 
two, or even more classes of glycoconjugate virulence factors without major impact on virulence, 
and only the absence of all classes could lead to complete loss of parasite virulence. 
Since targeting single virulence factors did not seem to lead to breakthrough in unfolding the 
mystery of Leishmania virulence, based on our novel approach, when the pathway of 
glycoconjugate biosynthesis was targeted, a new paradigm is arising that strongly suggests that 
instead of a single pinpointed mannose-containing glycoconjugate, the various glycan motifs that 
share considerable structural and functional redundancy between different classes of 
glycoconjugates, may be responsible for evolutionarily successful virulence of Leishmania. 
Our studies identify the mannose activation pathway of Leishmania as a virulence pathway 
that can be an attractive target for the development of novel anti-leishmanial drugs. Moreover, such 
a drug would be expected being effective more broadly against pathogens, since for example in 
pathogenic fungi the functional lack of the mannose activation pathway was shown leading to a 
lethal phenotype. The herein generated avirulent mutants most likely with suitable adjuvant may 
also be attractive subjects of vaccine development to prevent leishmaniasis (Garami A. unpublished 
results; Stewart J, 2005). 
The remarkable observation that Leishmania is the first eukaryotic organism with complete 
blockage of mannose activation pathway and without any consequent effect on viability makes L. 
mexicana parasites a unique eukaryotic model system for studying mannose-containing 
glycoconjugate biosynthesis by reverse genetics. Certainly, this may also allow identifying various 
transferases that are responsible for the assembly of the redundant glycan motifs implicated in 
Leishmania virulence. 
Taken together, these observations indeed envision a paradigm change of Leishmania 
virulence and call for revisiting the role of Leishmania glycoconjugate virulence factors based on 
the importance of shared glycan motifs. This road may lead us to a new horizon of understanding 
leishmaniasis, the disease and consequently to develop better disease control strategies, such as new 
medications and vaccine based prevention. 
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8. Materials and Methods (see in corresponding Annex) 
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